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ABSTRACT 
Otitis Media with Effusion (OM E) is a common childhood condition leading to 
hearing loss, and its treatment with ventilation tubes (VTs) is one of the 
commonest surgical procedures. However, aetiology of OME is poorly 
understood, and its current treatment requires improvement as OME 
frequently recurs once VTs extrude. 
The first, clinical part of this thesis showed that 63.6% of children randomised 
to VT insertion in a clinical trial will require VTs again, and even with additional 
adenoidectomy the need for repeat surgery remains high. Although published 
national guidelines set out criteria for surgery, the multicentre study presented 
here showed that only 32.2% of children that had VTs met these criteria, and 
guidelines' publication had limited impact on clinical practice. 
The second, laboratory part of this thesis demonstrated the importance that 
bacteria and biofilms play in aetiology of OME, as live bacteria were 
demonstrated in 91.9% of middle ear effusions (using culture and confocal 
microscopy). Following from this, a Staphylococcus aureus biofilm model was 
developed, and used to show that biofilm eradication requires antibiotic 
(rifampicin and clindamycin) levels 1,000 times higher than those required to 
inhibit planktonic bacteria, over a period of 2-3 weeks. To achieve this in the 
middle ear, a local delivery strategy using biodegradable poly (Iactic-co-
glycolic acid) antibiotic pellets was proposed. Drug release from these pellets 
11 
was investigated with High Performance Liquid Chromatography and Serial 
Plate Transfer Testing, which demonstrated that antibiotics can be released 
for up to 3 weeks. Importantly, the pellets were able to eradicate biofilms in 
the in vitro model. 
This thesis has shown that current OME treatment has significant deficiencies, 
but better understanding of OME pathogenesis raises the possibility of rational 
new therapeutic strategies. Biodegradable antibiotic pellets designed to 
eradicate OME biofilms may be a better future treatment that could improve 
the lives of countless children. 
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1 PRECIS 
Otitis media with effusion (OME, glue ear) is a common cause of hearing loss 
in childhood, affecting up to 80% of children at some stage at least for a 
limited time period. Treatment with grommets (ventilation tube, VT) insertion is 
one of the commonest surgical procedures in children in the developed world, 
and over 30,000 VTs are inserted in England each year. However, this 
treatment is far from ideal, as up to 25% of treated children have to have 
surgery more than once. 
Despite its common nature many questions surround OME, and this thesis 
aims to address some of the current deficiencies in our knowledge of this 
condition and its treatment. In addition to laboratory-based research, the 
project also investigates a number of clinical aspects. 
The clinical part of the thesis assesses recurrence after grommet extrusion, 
and details why further OME research is required. The role of adjuvant 
adenoidectomy in reducing need for revision surgery is examined. Current 
treatment is guided by the National Institute for Health and Clinical Excellence, 
and therefore actual clinical practice is compared with the guidelines, and the 
impact of guideline introduction assessed in a multi-centre project. 
The main, laboratory-based, part of the thesis starts by consolidating the 
existing microbiology data obtained by our group, demonstrating a crucial role 
for bacteria and biofilm in OME. Given the new understanding of OME 
pathogenesis and the limitations of current treatments, a novel therapeutic 
strategy is then explored. This centres on the use of high dose modified-
release antibiotics, and this strategy is explored in a newly-developed in vitro 
model. A biodegradable antibiotic modified-release pellet is examined, 
assessing drug release with High Performance Liquid Chromatography and 
with Serial Plate Transfer Testing, and the effectiveness of the pellet against 
biofilms is tested in the in vitro model. 
2 
2 INTRODUCTION 
2.1 OTITIS MEDIA WITH EFFUSION 
Otitis media with effusion (OME, glue ear) is a common childhood condition. It 
is the commonest cause of deafness in children in the developed world with 
prevalence in the region of 20% (Mandel, et al. 2008), and up to 80% of 
children affected at least temporarily by the age of 10 years (Bluestone, 
Stephenson and Martin 1992). It is characterised clinically by hearing loss due 
to a middle ear effusion (thick fluid behind the ear drum) in the absence of 
symptoms or signs of acute inflammation, and pathologically by chronic 
inflammation of middle ear mucosa leading to the production of a mucin-rich 
effusion. 
Although in majority of cases OME is transient, a proportion of children 
develop persistent symptoms that affect hearing, education, language or 
behaviour (Hall, Maw and Steer 2009) (NICE 2008). OME can also be a 
precursor to tympanic membrane (TM) retraction (TM becoming sucked into 
the middle ear), perforation, or cholesteatoma (skin in the middle ear). If OME 
persists after a three month period of watchful waiting and has a Significant 
impact on the child, treatment with ventilation tubes (VTs, grommets) may be 
considered (Lous, et al. 2005) (NICE 2008). VT insertion is one of the 
commonest indications for surgery in the developed world (Kubba, Pearson 
3 
and Birchall 2000), and over 30,000 VTs were inserted in England during 
2005/6 (HES 2010). OME and related acute middle ear infections (acute otitis 
media, AOM) are the leading cause of primary care visits (Freid, Mukuc and 
Rooks 1998), and the most frequent reason for antibiotics or surgery 
(Keyhani, et al. 2008) (Rovers, et al. 2004). Annual costs in the USA were 
estimated to be in excess of $5 billion in 1998, but this is likely to have risen 
by now, and indirect costs are likely to be higher still (Bondy, et al. 2000). 
OME, acute otitis media and recurrent AOM (RAOM, 3 or more episodes in 6 
months) are closely related clinical conditions (Alho, et al. 1995), with AOM 
representing an acute infective (bacterial and/or viral) process, whereas OME 
is characterised by the presence of a middle ear effusion in the absence of 
symptoms and signs of acute inflammation (Kubba, Pearson and Birchall 
2000). AOM differs from OME in that AOM is characterised by ear pain and 
fever in a child that is systemically unwell. In some cases the pain is followed 
by ear discharge as the tympanic membrane perforates, and the resultant 
release of pus under pressure leads to improvement in pain. Several other 
clinical entities are characterised by inflammation of the middle ear ("otitis 
media"), shown in Fig 2.1.1, with ear anatomy illustrated in Fig 2.1.2. 
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Otitis Media 
acute 
o 
acute otitis media: acute infection in middle ear 
recurrent acute otitis media : 3 or more episodes in 6 months 
chronic 
otitis media with effusion: middle ear effusion in absence of symptoms 
or signs of acute inflammation 
chronic suppurative otitis media: middle ear inflammation, usually with 
tympanic membrane perforation 
cholesteatoma: squamous epithelium in the middle ear, leading to 
inflammation 
c 
E F 
Fig 2.1 .1: Different types of Otitis Media (top box) and clinical photographs 
showing normal TM (A), acute otitis media (B) , dull tympanic membrane in 
otitis media with effusion (C), ear drum perforation (D), retraction (E) and 
cholesteatoma (F). ME: middle ear. TM: tympanic membrane. A and D-F 
(Flint, et al. 2010); Band C (Datta 2012). 
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Fig 2.1.2: Ear anatomy (NYSDOH 2011) 
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OME is diagnosed (Browning 1998) on the basis of a history of hearing loss. 
speech delay (typically mispronunciation rather than lack of vocabulary). or 
educational concerns. in some children associated with episodes of AOM (ear 
pain, fever, perhaps followed by discharge). Otoscopy can reliably make the 
diagnosis if carried out by an experienced operator. with diagnosis being 
confirmed by tympanometry and hearing assessment. Tympanometry 
measures the sound reflected from the ear drum while the pressure of the 
external canal is varied by the operator. Normally the maximum sound 
reflection occurs at atmospheric pressure. but in OME the sound is typically all 
absorbed by the fluid in the middle ear leading to a flat tympanogram (Fig 
2.1.2). A flat tympanogram is also obtained in patients with tympanic 
membrane perforation. but this is easily distinguished from OME by clinical 
examination and by the finding of a large canal volume measured at 
tympanometry. as the volume measured then represents not only the volume 
of the ear canal but also the volume of the middle ear measured through the 
perforation. On audiometry. whether standard pure tone audiometry or 
methods suitable for children, a mild conductive hearing loss is present (Fig 
2.1.3); hearing level is by convention measured on a biological logarithmic 
scale compared to normal hearing (decibel Normal Hearing Level. dB NHL), 
with anything between 0 and 20 dB NHL considered within normal limits. 
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Fig 2.1 .3: Audiometry showing normal hearing in the right ear (A) and mild 
conductive loss on the left (B) (McGill 2010). 
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2.2 CURRENT MANAGEMENT OF OME 
2.2.1 Ventilation Tubes and NICE Guidelines 
Ventilation Tube (Fig 2.2.1.1) insertion is currently the only effective and UK-
recommended treatment to restore hearing (NICE 2008) but requires a 
general anaesthetic in children. A variety of different tubes are available, 
ranging from the short term (typically 6-9 months) Shepard tubes, through 
Shah and Reuter bobbins, to T-tubes and Permavents that stay in place for 
several years. The longer a tube stay in the more likely it is to lead to 
problems, with a persistent perforation rate of 5.6% reported in Shah 
grommets (Vaman, et al. 2010), but occurring in more than 10% if long term 
ventilation tubes are inserted (Saito, et al. 1996). 
Fig 2.2.2.1: Ventilation tubes 
Numerous medical treatments have been tried in order to avoid surgery. 
Antibiotics particularly have received considerable attention (Rosenfeldt and 
Bluestone 1999) (Rovers, et al. 2004). Although oral antibiotics are effective in 
the short term, increasing OME resolution rate by about 15% (Rosenfeldt and 
9 
Bluestone 1999) (Rosenfeld and Post 1992), this benefit is short lived and 
there is no significant advantage after a few month (Gunasekera, et al. 2009) 
(Rosenfeldt and Bluestone 1999) (Rovers, et al. 2004) (Williams, et al. 1993). 
Antibiotics are not a recommended treatment in the UK (NICE 2008), nor are 
steroids, decongestants, or antihistamines. 
The prevailing current treatment strategy, based on NICE guidelines on the 
surgical management of OME (NICE 2008), is VT insertion in children with 
symptomatic persistent bilateral OME documented over a period of 3 months 
with a hearing level in the better ear of 25-30 dB NHL or worse. The 
observation period is suggested due to high incidence of spontaneous 
resolution, and only children that are being affected by OME (for example with 
speech delay or schooling problems) should undergo surgery. The guidelines 
are clear that surgery is inappropriate for children that have OME only for a 
short time period or in cases where OME has little effect on child's function 
and development; this contrasts with older clinical practice and trials that 
assessed children that were very much at the mild end of the spectrum. 
The aim of any guideline (systematic statement of best evidence-based 
practice to assist doctors and patients in decision making about appropriate 
healthcare in specific circumstances (NHS Centre for Reviews and 
Dissemination 1994» such as NICE Guidance on surgical management of 
OME is to inform and standardise best practice. However, whilst guidelines 
should lead to improved patient care, this is by no means seen universally 
(Freemantle, et al. 2000) (NHS Centre for Reviews and Dissemination 1994) 
10 
(Oxman, et al. 1995). Much OME literature pOints to great variations in surgery 
rates and frequent non-compliance with guidelines. 
The odds of surgery for OME/AOM were noted to vary 4 fold across different 
regions of Norway in 2002 (Karevold, et al. 2007), and up to 10 fold for AOM 
across different countries (UK lowest) (Schilder, Lok and Rovers 2004). There 
was also a 10 fold variation in VT rates within Ontario in Canada in the late 
1990s (Coyte, et al. 2001), this variation being larger than that seen in almost 
any other procedure. Higher socio-economic status and the enthusiasm of the 
primary care doctor for VTs were associated with increased VT rates. An 
American study in 2002 found that >90% of VTs were not inserted in 
accordance with guidelines in place at the time, and 80% were not appropriate 
according to criteria developed by an expert panel for the study (Keyhani, et 
al. 2008). Even after excluding children with other conditions predisposing to a 
poor developmental outcome, those requiring other surgery, or those that 
have had VTs before, the number of appropriate VTs was still less than 40%. 
Going back several decades, the number of VTs in the UK was considered 
excessive, and guidelines published in 1992 (NHS Centre for Reviews and 
Dissemination 1992) emphasised the fact that for many children OME was a 
temporary phenomenon due to spontaneous resolution and watchful waiting 
should be the norm for most. The rates of OME surgery in England halved 
during the 1990s, and although the guidelines undoubtedly contributed, there 
was already an existing downwards trend in surgery rates (Black and 
Hutchings 2002). 
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Several possible explanations exist for the variation in surgery rates, ranging 
from differences in clinical opinion on diagnosis and effectiveness of 
treatment, to parental preferences, and perhaps even financial factors. Of 
course the problem may not be that surgeons are ignoring the guidelines, it 
may be that the guidelines are over-restrictive and do not allow 
personalisation of care to each individual child. 
Whilst the recent NICE guidelines on the surgical management of OME have 
clarified best practice, it is not yet known whether they have had an impact on 
OME treatment, nor whether there is a variation in compliance across different 
hospitals. 
2.2.2 Adenoidectomy 
Despite VT insertion, about a quarter of children will require further surgical 
treatment within 2 years (Gates, Avery and Prihoda 1987). In order to reduce 
recurrence, adenoidectomy as an adjunct to VT insertion has been 
investigated by several studies (Rosenfeldt and Bluestone 1999). 
Gates et al (Gates, Avery and Prihoda 1987) followed up 254 children aged 4-
8 years for 2 years. VTs+ad reduced time with effusion (26% of visits vs. 35%) 
and halved the need for further surgery (14% vs. 28%). Maw (Maw and 
Bawden 1994) followed up 222 children aged 3-9 years for up to 10 years. At 
5 years, VTs+ad had half the re-treatment rate of VTs alone: 34 vs. 68%. At 
10 years mean numbers of VTs needed were 1.5 and 2.5, respectively; +ad 
also appeared to benefit hearing, the probable chief basis for the reduced 
12 
further treatment, for up to 4 years. A trial comparing VTs+ad with 
myringotomy +ad in 3-7 year old children concluded that hearing in both 
groups improved, but using VTs instead of a myringotomy conferred no 
additional advantage, the implication being that it is the adenoidectomy that 
gets children better (Popova, Varbanova and Popov 2011). A RCT looking at 
adjuvant adenoidectomy in 4-9 year-old children found that while VTs were 
responsible for most of the initial benefit (better than myringotomy), adjuvant 
adenoidectomy increases the likelihood of restoration of normal middle ear 
function at least up to 2 years after surgery (Black, et al. 1990). In contrast, a 
study in children aged 2-3 years found that adenoidectomy conferred no 
advantage in terms of time with effusion over VTs alone (Casselbrant, et al. 
2009), and another (small - 72 patients) trial found that neither VTs nor 
VTs+ad influenced OME resolution compared with no surgery at 12 months 
(Dempster, Browning and Gatehouse 1993). Importantly, a large study of 
>50,000 children aged under 10 years found that adenoidectomy in addition to 
VTs reduced the need for subsequent surgery from 36% to 20% (Kadhim, et 
al. 2007). 
A 1992 review in Effective Health Care concluded that adding adenOidectomy 
to VTs only had a small effect up to 12 months post op (NHS Centre for 
Reviews and Dissemination 1992). A Cochrane review in 2010 concluded that 
adenoidectomy has a Significantly beneficial effect on OME resolution, 
although only a small benefit to hearing (van den Aardweg, et al. 2010). 
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In the UK adjuvant adenoidectomy is not recommended in the absence of 
persistent and/or frequent upper respiratory tract symptoms (NICE 2008). 
Whilst American guidelines agree with UK stance in the case of primary 
surgery, they recommend that adenoidectomy is undertaken in conjunction 
with any revision surgery (Rosenfeld, et al. 2004). This is because the role of 
adjuvant adenoidectomy is set in part by issues of risk (chiefly bleeding) rather 
than purely (cost-) effectiveness. There is not an evidence-based consensus 
about exactly who should receive adenoidectomy or when. The fact that many 
children do not require a second set of tubes is used to argue against 
adenoidectomy. There is a great variation in the number of children receiving 
adenoidectomy in different countries, but on the whole the number of children 
having adenoidectomy appears to be reducing (Haapkyla, et al. 2008). The 
NICE guidelines on surgical management of OME commented on the 
generally poor quality of adenoidectomy trials, calling for better quality 
research to evaluate any benefits of adenoidectomy (NICE 2008). 
A great degree of controversy surrounds adjuvant adenoidectomy in 
conjunction with VTs to try and reduce high rate of further surgery after VT 
extrusion, leading to the setting up of a multicentre UK study on glue ear 
treatment. The MRC Trial of Alternative Regimens on Glue ear Treatment 
(TARGET) examined children up to 2 years after randomisation to VTs, 
VTs+ad or watchful waiting, and found that adjuvant adenoidectomy benefits 
hearing for the 2 year duration of the trial (Browning 2012) (MRC Multicentre 
Otitis Media Study Group 2001a) (MRC Multi-Centre Otitis Media Study Group 
2001b). However, the follow-up period was only 2 years, but OME often lasts 
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much longer. Therefore, longer-term data is also of value, warranting 
supplementary studies beyond the TARGET 2 years (TARGET and the long-
term supplementary study presented in this thesis is described in more detail 
later). 
2.2.3 Evaluating OME treatment: which children to study and for how 
long? 
OME is a temporary phenomenon in most children. When discovered on 
screening of asymptomatic children, it resolves in 63% by three months and in 
88% by one year (Rosenfeldt and Bluestone 1999). The NICE guidelines have 
taken this into account as treatment is inappropriate for most children with 
incidentally discovered, short-term, unilateral or asymptomatic OME. 
The group of children where surgery may be considered are those with 
bilateral OME persisting at least three months. This group has a much lower 
spontaneous resolution rate (Maw and Bawden 1994) (Rosenfeldt and 
Bluestone 1999) (Table 2.2.3.1), with the median duration of OME being 7.8 
years (Maw and Bawden 1993). The surgical candidates, therefore, are a 
select group of children in whom untreated OME often follows a protracted 
relapsing and remitting course. 
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TIME OF FOLLOW UP (after OME PERCENTAGE OF CHILDREN IN 
has already been present 3 months) WHOM OME HAS RESOLVED 
6 months 27% 
1 year 32% 
2 years 31% 
3 years 49% 
4 years 59% 
5 years 69% 
7 years 85% 
10 years 95% 
Table 2.2.3.1: Spontaneous resolution rate In children with bilateral OME that 
has already persisted for 3 months at the start of the trial (Maw and Bawden 
1994) (Rosenfeldt and Bluestone 1999). 
This complex evolution of the natural history of OME raises difficulties for the 
evaluation of treatments, as some patients may improve without treatment, 
whereas others suffer recurrence after VT extrusion. Any ReT therefore faces 
the issue of appropriate time scale through which to evaluate a treatment. 
The natural efficacy of most VTs is in the region of 6-9 months, the time that 
VTs stay in place before being spontaneously ejected. Therefore, evaluating 
VTs over 12 months is a sensible initial trial duration that takes in the VT stay 
period. However there is no such clearly defined evaluation period for 
treatments other than VTs, for example adjuvant adenoidectomy or any new 
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techniques. Most trials evaluate outcomes over at least 2 years to take 
account not only of VT stay time but also of the recurrence after VT extrusion, 
but longer term data is rare (Rosenfeldt and Bluestone 1999). 
The two year follow up was also adopted by TARGET, the Trial of Alternative 
Regimens in Glue Ear Treatment (Browning 2012) (MRC Multi-Centre Otitis 
Media Study Group 2001 b) (MRC Multicentre Otitis Media Study Group 
2001a), a major UK multi-centre RCT designed to evaluate OME treatment 
over a 2 year period on children aged 3.5 to 7 years. TARGET's main entry 
criterion was 20 dB NHL or worse in the better-hearing ear on initial visit, and 
the same again after 3 months. Those qualifying and accepting randomisation 
(376 children) were then randomised to VTs, VTs+ad, or further active 
observation (FAO). A further adjunct cohort of 56 children, with hearing worse 
than 40dB NHL that were thought to have an overriding need for treatment, 
were also treated and given discretionary adenoidectomy. Subject to 
reservations about non-randomised analysis, this group, known as "obliged to 
treat" (On), boosts the numbers for comparing VTs+ad with VTs alone or 
FAO. 
Children were followed up for 2 yrs. There was spontaneous remission in 
about a third of FAO children; however, overall 62% of children allocated to 
FAO switched to a surgical treatment arm within 1 year, emphasising the 
clinical need of this OME population as a whole. VTs led to better hearing 
outcomes initially, but after 1 year there was no advantage of VTs over FAO. 
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TARGET entry criteria ensured that only the severe spectrum of OME was 
captured, as evidenced by the high switching from FAO to surgery. Studies 
that adopt less stringent entry criteria have questioned the benefits of VTs. For 
example, the widely quoted Paradise study (Paradise, et al. 2007) included 
children purely on the basis of the presence of effusion even if unilateral, 
accepted 15dBHL as the audiometric criterion, and analysed largely children 
under 2 years old. Their findings of limited benefits of VTs are not surprising 
as they studied a group of children that likely did not have much of a problem 
in the first place. A benefit of VTs in terms of language, writing and behaviour, 
both while VTs are in-situ and after extrusion, has been demonstrated by UK-
based studies on the more severely affected children (Hall, Maw and Steer 
2009) (Wilks, et al. 2000). 
Although most OME trials look at a two year period that encompasses VT stay 
time and the period immediately after extrusion, the chronic nature of OME 
should ideally also be taken into account, although exactly how long any trial 
should last is unclear. 
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2.3 AETIOLOGY OF OTITIS MEDIA WITH EFFUSION 
Despite its major socio-economic and health care importance, the aetiology of 
OME is only now being elucidated (Rovers, et al. 2004). It is a chronic 
inflammatory condition affecting the middle ear mucosa resulting in mucus 
secretion that accumulates in the middle ear cleft (Kubba, Pearson and 
Birchall 2000). The middle ear mucosa constantly secretes mucus, which is 
then moved down the Eustachian tube. The mucus has a protective function, 
as it provides a physical barrier and prevents adhesion of bacteria to mucosa. 
Upon irritation, the mucosa responds by increasing the production of mucus 
and secretion of altered mucus types (Kubba, Pearson and Birchall 2000), 
goblet cells proliferate, and new mucous glands form (Bak-Pedersen and Tos 
1976) (Tos 1980) (Tos and Caye-Thomasen 2002). 
In addition to mucins, middle ear effusions also contain water, cells, cell 
debris, electrolytes and various other high molecular weight compounds such 
as proteins, lipids, and DNA. Bacteria and their product have also been 
identified, as have immunoglobulins, lysozyme, lactoferrin, complement, 
leukotrienes and cytokines. While many of these may be present as a result of 
bacterial inflammation, mucins are actively secreted into the effusion 
(Smirnova, et al. 2003); OME is an exudate, not a transudate. 
Whilst it is clear that OME develops as a result of mucosal irritation, the cause 
of the initial inflammatory stimuli has been difficult to establish (Kubba, 
Pearson and Birchall 2000). 
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2.3.1 Bacteria in OME 
Whilst OME is a chronic inflammatory condition on histology, the cause of the 
inflammatory stimulus that leads to production of mucins and an effusion has 
been difficult to identify. Some of the risk factors for OME (young children, 
association with AOM, day-care, many siblings, lack of breastfeeding) suggest 
an infective aetiology, but OME is not characterised by symptoms and signs of 
acute inflammation that would be expected in a typical acute bacterial 
infection with a bulging red tympanic membrane, pain and fever. 
The role of bacteria in OME has therefore been controversial. In most studies 
bacteria could be cultured in fewer than half of samples, ranging from 21 to 
70% (Bluestone, Stephenson and Martin 1992) (Gok, et al. 2001) (Hall-
Stoodley, Hu, et al. 2006) (Hendolin, et al. 1997) (Matar, et al. 1998) (Poetker, 
et al. 2005) (Schousboe, et al. 2001). Although this may suggest that bacteria 
are not important in OME, it contrasts with studies examining effusions for the 
presence of bacterial nucleic acids by polymerase chain reaction (peR), 
which have demonstrated bacterial DNA typically in excess of 80% of 
effusions (Hendolin, et al. 1997) (Kubba, Pearson and Birchall 2000) (Post, 
Preston, et al. 1995) (Rayner, et al. 1998). However the presence of bacterial 
nucleic acids does not equate to the presence of viable bacteria, and 
components of effusion samples have been shown to inhibit nuclease activity, 
perhaps leading to persistence of RNA and DNA even if bacteria are no longer 
viable (Peizhong, et al. 2000). 
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A possible explanation for the discrepancy between high PCR-positive rate 
and low culture-positive rate in OME is involvement of biofilms (Fergie, et al. 
2004), as these may give culture-negative results in the laboratory (biofilms 
are described later). Indeed, biofilms have been identified on human middle 
ear mucosa in children with OME and/or recurrent AOM in 65 - 92% of cases, 
but not in any control samples studied (Thornton, et al. 2011 )(Hall-Stoodley et 
al 2006). Biofilms have also been identified in animal models of OME (Ehrlich, 
Veeh, et al. 2002) (Post 2001). However, a study of middle ear mucosal 
biopsy at time of cochlear implant showed biofilms in 2 out of 45 cases without 
evidence of previous otologic problems or abnormalities, suggesting that 
biofilms may exist in the asymptomatic middle ear (Tonnaer, Mylanus, et al. 
2009). Biofilms have also been found in patients with cholesteatoma (Chole 
and Faddis 2002) and chronic suppurative otitis media (Hom0e, et al. 2009). 
In addition to biofilms, bacterial persistence may also occur due to intracellular 
infection (Coates, et al. 2008), perhaphs co-existing with biofilm (Thornton, et 
al. 2011). 
A wide range of bacteria have been implicated in OME. The commonest 
bacterial isolates are Streptococcus pneumoniae, Moraxella catarrhalis and 
Haemophilus influenzae, with Staphylococcus aureus and many others also 
frequently reported (Bluestone, Stephenson and Martin 1992) (Hyden, 
Akerlind and Peebo 2006). 
In addition to suggestions that OME is a biofilm disease, it is also thought that 
the benefits of adenoidectomy are linked to removal of nasopharynx biofilms. 
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Adenoid tissue acts as a reservoir of bacteria: bacteria in the middle ear get 
there by ascending via the Eustachian tube from the nasopharynx and 
adenoid tissue (Tonnaer, Rijkers, et al. 2005). Adenoidectomy alters the 
nasopharyngeal bacteria, reducing the incidence of carriage of Haemophilus 
influenzae and Streptococcus pneumoniae (Aarts, et al. 2010), and adenoid 
tissue of children with OME has been shown to contain bacterial biofilms 
(Hoa, et al. 2010) (Kania, et al. 2008) (Nistico, et al. 2011) (Winther, et al. 
2009). However, adenoid tissue contains bacteria even in absence of OME 
(Nistico, et al. 2011), and the adenoid bacteria may be no different in those 
children with OME from those without (AI mac, et al. 2009). 
2.3.2 Other theories of OME aetiology 
Several other theories of OME aetiology have been investigated in the past 
(Kubba, Pearson and Birchall 2000). The unifying pathway is inflammation 
leading to production of more and thicker mucus which accumulates in the 
middle ear, in conjunction with impaired mucociliary clearance due to the 
increased mucus viscosity. Figure 2.3.2.1 presents an integrated model of 
OME aetiopathogenesis. 
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Fig 2.3.2.1: OME aetiopathogenesis. ME: middle ear. ET: Eustachian tube 
Eustachian tube function has received a lot of attention, but aetiology of OME 
is much more complex than Eustachian obstruction. If OME developed as a 
result of a physical Eustachian tube obstruction, then the fluid would be a 
transudate and not an exudate (Kubba, Pearson and Birchall 2000). Another 
factor pointing against Eustachian tube blockage can be inferred from results 
of treatment with VT insertion: one study of children having VTs inserted 
aspirated fluid only on one side but not the other. If the Eustachian tube was 
blocked, then the fluid left in the middle ear should drain out through the VT, 
but in fact the effusion dissipates down the Eustachian tube, suggesting that 
there was no physical blockage of the Eustachian tube (Sade, Halevy and 
Hadas 1976). Eustachian tube dysfunction (as opposed to obstruction) may 
23 
be involved as the tube is the likely source of bacteria in the middle ear 
ascending from the adenoids I nasopharynx, and its function may be affected 
by acute bacterial or viral infections (Rosenfeldt and Bluestone 1999). 
Smoking causes impaired ciliary action, but is in itself unlikely to be the 
predominant cause of OME as children not exposed to passive smoking still 
get OME (Sophia, et al. 2010). Ciliary beat frequency in children with effusion 
is no different from those without (-11 Hz) (Wake and Smallman 1992). Viral 
DNA has also been identified in the middle ear, but a causal relationship to 
OME has not been established (Pitkaranta, et al. 1998). Atopy is a weak risk 
factor at the most (Caffarelli, et al. 1998) (Sophia, et al. 2010). Diesel exhaust 
fumes have been shown to decrease cell viability, induce inflammation, and 
increase mucin expression in middle ear epithelial cell cultures (Song, et al. 
2012). 
Genetic aetiology has been investigated in mouse models (Hardisty-Hughes, 
et al. 2006) (Parkinson, et al. 2006). However, there is no good animal model 
of OME, and at least some of the animal mutants with OME have associated 
craniofacial abnormalities. Also, the effusion composition has not been studied 
to demonstrate comparability with humans, and the observation of different 
effusion components between the right and the left ear (Johnson, et al. 1997) 
suggests that genetic influences alone are unlikely to be responsible for OME, 
although they may influence the host interaction with pathogens or the 
inflammatory response. 
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The aetiology of OME is unclear, but the role of bacteria and biofilms warrants 
further investigation using new methods that can demonstrate bacteria in the 
middle ear effusion. 
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2.4 BACTERIAL BIOFILMS AND THEIR TREATMENT 
2.4.1 Pathogenesis of biofilm infections 
Bacteria exists in two forms, planktonic and biofilms. Planktonic bacteria are 
free-floating unicellular organisms, allow rapid dissemination over a large 
area, and have been successfully targeted by antibiotics. On the other hand, 
bacterial biofilms, now known to be present in virtually all natural and 
pathological environments, are emerging as major causes of human disease 
(Vlastarakos, et al. 2007), being focused on persistence and characterised by 
their recalcitrance to antibiotics and clearance by host defence mechanisms 
(Donlan and Costerton 2002). It has been estimated that >60% of infections 
are caused by biofilms (Lewis, Riddle of Biofilm Resistance 2001). Although 
probably first described in the seventeenth century by Anton van 
Leeuwenhoek's examination of his own dental plaque, universal acceptance 
of biofilms in human pathogenesis has only occurred in the last few decades 
(Schinabeck and Ghannoum 2006). Bacteria grown as colonies on an agar 
plate are thought to be most similar to planktonic bacteria (Mikkelsen, et al. 
2007), so the study of biofilms requires new, different methods. 
Biofilms are structured communities of bacteria embedded in a self-produced 
extracellular matrix attached to a surface or interface (which may be 
surrounding mucus or fluid) (Yang, et al. 2008), and exhibiting altered 
phenotype with respect to growth rate and gene transcription (Donlan and 
Costerton 2002) (Hall-Stoodley and Stood ley 2009) (Schinabeck and 
Ghannoum 2006). The last characteristic distinguishes them from those 
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bacteria attached to surfaces but not exhibiting the altered phenotype, for 
example bacteria growing on agar. Biofilms can be composed of single or 
multiple species. They are not homogeneous monolayers of bacteria on a 
surface, but are composed of bacterial micro-colonies (accounting for -15% of 
the biofilm volume) encased in matrix (-85%) (Fig 2.4.1.1) (Donlan and 
Costerton 2002) (Lawrence, et al. 1991) (Rasmussen and Lewandowski 
1998). 
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o resistant to abx 
0 2 gradient 
pH gradient 
nutrients 
Figure 2.4.1.1: Schematic biofilm structure 
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When a planktonic bacterium arrives at a surface it become reversibly 
attached in the first instance (Pascual 2002) (Schinabeck and Ghannoum 
2006). The close proximity allows irreversible adhesion to occur, which 
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depends on direct interaction between bacterial ligands and the host / surface 
(Gristina 1987). Adhesion of bacteria to a surface triggers a change in 
phenotype (Otto 2008), with biofilms forming as fast as within 24 hours 
(Nickel , et al. 1985) (Oliveira, et al. 2007) (Vorachit, et al. 1993). Once 
irreversibly adherent, cell proliferation and biofilm formation occurs (Fig 
2.4.1.2) (Schinabeck and Ghannoum 2006). In addition to tissue surfaces, 
biofilms have also been identified attached to collagen gel matrix (Werthen , et 
al. 2010) and mucus (Corazziari 2009) (Werthen, et al. 2010) (Winther, et al. 
2009) (Yang, et al. 2008). In OME, biofilms could be attached to mucus as 
well as mucosa, and the resultant inflammatory stimulus may then lead to a 
middle ear effusion (Hunter, et al. 1999) (Schousboe, et al. 2001) (Smirnova, 
et al. 2002) (Sun, et al. 2012). 
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Figure 2.4.1.2: Biofilm life cycle 
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Biofilms cause disease in a number of ways (Donlan and Costerton 2002). 
Parts of the biofilm can break off (Gristina 1987) (Stoodley, et al. 2001) when 
the tensile strength is exceeded, resulting in septic embolisation, and biofilms 
can also shed planktonic bacteria leading to distant spread. Bacteria can 
induce a host response through the production of endotoxins (Vincent, Tibi 
and Darbord 1989), but biofilms themselves may be less susceptible to host 
immune response (Hall-Stoodley and Stoodley 2009) (Shiau and Wu 1998) 
(Ward, et al. 1992) (Yasuda, et al. 1994), and the close proximity of bacteria 
may encourage the transfer of plasm ids even between bacteria of different 
genera (Ehlers and Bouwer 1999). 
2.4.2 Criteria for a biofilm infection 
Many infections have been associated with biofilm formation (Donlan and 
Costerton 2002) (Hall-Stoodley and Stoodley 2009). Parsek and Singh 
suggested that the criteria in Table 2.4.2.1 should be fulfilled for a disease to 
be considered a biofilm infection (Parsek and Singh 2003). 
Parsek and Singh criteria for biofilm infections 
Bacteria are adherent to substratum or a surface 
Bacteria living in cell clusters or micro-colonies encased in extracellular matrix 
Infection generally confined to a particular location 
Infection difficult or impossible to eradicate with antibiotics, despite the 
responsible bacteria being susceptible when in the planktonic state 
Table 2.4.2.1: Parsek and Singh criteria for biofilm infections (Parsek and 
Singh 2003) 
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2.4.3 Studying bacterial biofilms in vitro 
A number of different ways of studying biofilms in vitro have been described, 
with several important parameters to consider (Donlan and Costerton 2002): 
Medium: composition, temperature, presence of antimicrobials 
Inoculum: Identity of organism, number of cells 
Hydrodynamics: flow rate, presence of shear 
Substratum: roughness, chemistry, conditioning film 
The in vitro biofilm models are broadly similar in that they all rely on the 
provision of a surface for bacterial attachment and a nutrient environment. 
Some surfaces are more conducive to biofilm formation than others, with latex 
and silicone being most supportive of bacterial attachment, followed by 
Poly(vinyl chloride), Teflon (poly(tetra fluoro ethylene)), polyurethane, 
stainless steel and titanium (Darouiche 2001) (Pascual 2002) (Schinabeck 
and Ghannoum 2006), although not all studies agree (Bayston, Ashraf and 
Barker-Davies, et al. 2007). Surfaces that are rough or irregular have 
enhanced bacterial attachment, as do those that are hydrophobic or positively 
charged as they attract bacteria that are predominantly hydrophobic and 
negatively charged in their planktonic state (Darouiche 2001) (Schinabeck and 
Ghannoum 2006). However, the characteristics of any implanted material can 
be altered by the presence of a "conditioning film" composed of several host 
components (fibronectin, fibrinogen, fibrin, albumin, collagen, elastin, von 
Willebrand factor), which may in some circumstances increase bacterial 
adherence (Pascual 2002) (Schinabeck and Ghannoum 2006). Rather counter 
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intuitively, bacterial adhesion is promoted by shear forces, with biofilms 
formed in high shear environments being stronger (Donlan and Costerton 
2002). 
In order to study OME biofilms and their eradication in the laboratory setting, a 
new in vitro model is required. Demonstration of biofilm structure as well as its 
functional characteristics, reduced susceptibility to antibiotics, will have to be 
shown. Because high dose antibiotics delivered locally over several weeks are 
likely to be required for biofilm eradication, the new model must be able to 
incorporate the addition of antibiotics or a modified release device sized for 
use in the middle ear. Although a number of well known biofilm systems have 
been used by other researchers, including the commercially available Calgary 
Biofilm Device (Minimum Biofilm Eradication Concentration (MBEC) assay 
system) (Ceri, Olson and Stremick, et al. 1999) and the CDC biofilm reactor 
(Goeres, et al. 2005), as well as the modified Robbins device (Lewis, Riddle of 
Biofilm Resistance 2001), the dimensions of these are not suitable for 
examining the effects of an added modified release device intended for use in 
the middle ear. Therefore a new in vitro biofilm model will have to be 
developed. 
In order to measure bacteria in biofilms on a surface, the biofilm can be 
removed from the surface using sonication or enzymes, and the resulting 
bacterial suspension plated to count the number of colony forming units (Ceri, 
Olson and Stremick, et al. 1999). Other methods assess biofilms in-situ by 
measuring the turbidity of nutrient broth (Ceri, Olson and Stremick, et al. 1999) 
31 
or the intensity of staining with crystal violet (Djordjevic, Wiedmann and 
McLandsborough 2002), but this does not allow the counting of colony forming 
units. An important step in the study of biofilms is the use of resuscitation tests 
where biofilms previously exposed to a treatment agent are then placed into 
fresh nutrient broth to determine whether any bacteria have persisted, and are 
capable of re-growing once the inhibitory effect of antibiotics is withdrawn. 
2.4.4 Treatment of biofilm infections 
Biofilms show inherently low susceptibility to treatment with antibiotics, 
typically requiring from 10 to 1000 times higher antibiotic levels than those 
required to inhibit planktonic bacteria (Ceri, Olson and Stremick, et al. 1999) 
(Donlan and Costerton 2002) (Nickel, et al. 1985) (Olson, et al. 2002) 
(Vorachit, et al. 1993). This reduced susceptibility to antibiotics, termed 
recalcitrance, is distinct from antibiotic resistance occurring as a result of 
genetic alterations. Resistance (Lewis 2001) is the ability of an organism to 
grow in the presence of elevated levels of an antimicrobial, yet biofilms do not 
show this as the bacteria in their planktonic state are as sensitive to 
antibacterials as expected; only when grown in a biofilm is the reduced 
susceptibility, the recalcitrance, evident. This recalcitrance arises as a result of 
several possible factors (Hall-Stoodley and Stood ley 2009) (Lewis, Riddle of 
Biofilm Resistance 2001) (Sihorkar and Vyas 2001). 
• Bacteria in biofilms are slow growing, rendering them relatively less 
susceptible to antibiotics (DuGuid, et al. 1990) (Evans, et al. 1990). 
• Adhesion to a surface and change to the biofilm phenotype influences the 
expression of a number of genes and phYSiologic parameters that may 
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affect susceptibility to antibiotics (Dagostino, Goodman and Marshall 
1994). 
• Within the biofilm structure a gradient of oxygen, pH, or nutrient levels 
exists (Rasmussen and Lewandowski 1998), and this gradient may affect 
antibiotics directly or change the growth of bacteria in the anaerobic micro-
niche at the centre of the biofilm (Hall-Stoodley and Stoodley 2009) 
(Proctor and von Humboldt 1998) (Sihorkar and Vyas 2001). 
• Biofilms contain "persister cells" that are not affected by antibiotics even 
when other biofilm bacteria are killed, perhaps due to expression of 
specific genes capable of shutting down antibiotic targets to create a 
dormant tolerant cell (Lewis 2001). This temporary state is distinct from the 
permanent and heritable resistance characterised by prevention of 
antibiotic binding to target in a cell that continues to be metabolically 
active. It is also not due to bacteria being at a specific point in the cell cycle 
and, although related to growth phase, is not identical with simply non-
growing cells (Lewis, Spoering, et al. 2006) (Shapiro, Nguyen and 
Chamberlain 2011). 
• Antibiotics have to penetrate the biofilm matrix to get to the bacteria, but 
the matrix may affect the diffusion of antibiotics so that their effectiveness 
is reduced. Not all antibiotics are thought to be affected equally, with 
rifampicin, clindamycin and macrolides thought to be relatively uninhibited 
(Souli and Giamarellou 1998). 
• These recalcitrance factors can act singly or in combination (Donlan and 
Costerton 2002). 
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As biofilms do not behave the same as planktonic bacteria, the use of 
planktonic bacteria-based Minimum Inhibitory Concentration (MIC) and 
Minimum Bactericidal Concentration (MBC) when discussing effects of 
antibiotics is inappropriate, leading to the use of Minimum Biofilm Eradicating 
Concentration (MBEC) instead (Ceri, Olson and Morck, et al. 2006). MBEC is 
typically in the region of 10 to 1000 times higher than MIC (Ceri, Olson and 
Stremick, et al. 1999) (Donlan and Costerton 2002) (Nickel, et al. 1985) 
(Olson, et al. 2002) (Vorachit, et al. 1993), and treatment over several weeks 
is typically required (R. Donlan 2008). However, whether that high antibiotic 
level is required for the full duration of treatment is not known, and it may be 
that an initial high level followed by a lower antibiotic level is satisfactory. 
Several broad approaches may be used against biofilm infection (Aslam 2008) 
(Donlan and Costerton 2002) (Sihorkar and Vyas 2001): 
• Prevention of initial contamination, e.g. by adhering to strict aseptic 
techniques. 
• Prevention of initial microbial attachment and biofilm development e.g. with 
antibiotic impregnated devices (Bayston, Ashraf and Bhundia 2004) 
(Bayston, Fisher and Weber 2009) or other device modification 
(Biedlingmaier, Samaranayaki and Whelan 1998) (Furno, et al. 2004). 
• Eradication of established biofilms with antibacterial agents (R. Donlan 
2008) (Sihorkar and Vyas 2001), delivered either systemically or locally: 
antibiotic bone cement, catheter antibiotic-lock therapy (R. Donlan 2008) 
(Fernandez-Hidalgo, et al. 2010), or novel drug delivery systems such as 
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liposomes or biodegradable polymers (Sihorkar and Vyas 2001) (Smith 
2005). Additionally, novel techniques may be used such as ultrasound 
(Ensing, et al. 2006) (Huang, et al. 1996), low-strength electrical fields 
(Blenkinsopp, Khoury and Costerton 1992), degradation of extracellular 
matrix (Johansen, Falholt and Gram 1997), inhibition of quorum sensing 
(Bassler and Losick 2006) (Diggle, Crusz and Camara 2007) (P. Williams 
2007), disruption of biofilm-related genes, or indeed a combination of the 
above in a smart system that detects and treats colonising infection 
(Ehrlich, Stoodley, et al. 2005). 
• Removal of infected surface. 
Eradication of established biofilm infections is notoriously difficult (Donlan and 
Costerton 2002) (Lewis 2001), but it is likely that high antibiotic concentrations 
with extended exposure periods will be required, with certain antibiotics (e.g. 
rifampicin and clindamycin) appearing to be better against biofilms than others 
(Lee, et al. 2006) (Souli and Giamarellou 1998). Those two antibiotics were 
therefore chosen for the study of biofilm eradication in this thesis. Additionally, 
the combination of two antibiotics minimises emergence of resistance 
(D'Agata, et al. 2008). 
2.4.5 Rifampicin and clindamycin 
The interaction between antibiotics and planktonic bacteria is described by 
MIC and MBC, and that between antibiotics and biofilms by the MBEC as 
explained above. Although these describe in vitro activity of antibiotics, they 
do not describe the time course. Antibiotics are divided into two broad 
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categories, time-dependent and concentration-dependent (Finch and Gander 
2006). Concentration-dependent antibiotics (aminoglycosides, quinolones) 
show an increase in the rate and the extent of bactericidal activity with 
increased concentration. With time-dependent antibiotics (beta-Iactams, 
linezolid, tetracyclines) the rate and extent of killing is dependent of time 
above a minimum concentration, but further increases in antibiotic 
concentration do not increase the cidal activity. Some time-dependent 
antibiotics also exhibit post-antibiotic effects. Antibiotics that are bacteriostatic 
inhibit the growth and reproduction of bacteria without killing them (relying on 
the immune system to kill bacteria), whereas bactericidal antibiotics kill 
bacteria. 
For the study of biofilm eradication, rifampicin and clindamycin were chosen. 
They appear to be better than other antibiotics at eradicating biofilms (Lee, et 
al. 2006) (Souli and Giamarellou 1998), the combination of two antibiotics 
minimises emergence of resistance (D'Agata, et al. 2008), and between them 
they cover common OME pathogens. 
In terms of their pharmacodynamic activity, the stratification of rifampicin and 
clindamycin into different types of antibiotics is not clear-cut. Rifampicin can 
be bacteriostatic or bactericidal depending on dose and exposure time, and 
exhibits time-dependent and also concentration-dependent killing (Bakker-
Woudenberg, et al. 2005) (Gumbo, et al. 2007). Similarly, clindamycin can be 
bacteriostatic or bactericidal depending on dose and exposure time, and 
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exhibits time-dependent (Klepser, et al. 1996) and also concentration-
dependent killing (Aldridge and Stratton 1991). 
Clindamycin, C1sH33CIN205S (Fig 2.4.5.1), molecular weight 425.0, is a 
lincosamide antibiotic that binds to the 50s subunit of the ribosome and 
interferes with protein synthesis. It is active against aerobic Gram-positive 
cocci including staphylococci and streptococci, and against anaerobic Gram-
negative rods, but most aerobic Gram-negative bacteria (Haemophilus, 
Moraxella) are resistant. 
Fig 2.4.5.1: Clindamycin (Sigma 2012) 
Rifampicin, C43H5SN4012 (Fig 2.4.5.2), molecular weight 823.0, inhibits DNA-
dependent RNA polymerase. It is active against most Gram positive cocci 
including Streptococci and Staphylococci, Haemophilus influenzae, as well as 
mycobacteria (Thornsberry, Hill, et al. 1983) (Thornsberry, Ogilvie, et al. 
1999). 
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Fig 2.4.5.2: Rifampicin (Sigma 2012) 
Although a single step mutation renders bacteria resistant and rifampicin is 
therefore not recommended for monotherapy, it has been found to be 
particularly effective in biofilm infections. Much information exists on using 
rifampicin in combination with other antibiotics, showing impressive results in 
the management of biofilm infections with a strong synergistic bactericidal 
activity (Barriere 2006). 
Thus eradication of biofilms with antibiotics appears to be a promising 
strategy, with rifampicin and clindamycin likely to be a good choice. Certainly 
treatment of OME could be improved, and the current high need for repeat VT 
insertion is not surprising if OME is a biofilm infection, because whilst VTs 
may remove the effusion to improve hearing, they do not deal with the 
underlying problem of a biofilm infection. A new, better treatment strategy 
based on understanding of OME pathogenesis is thus required. Biofilm 
eradication requires high antibiotic levels over several weeks, and therefore 
the use of a modified release formulation to deliver high dose antibiotics direct 
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to the middle ear is a potentially useful future strategy. Local delivery achieves 
high enough antibiotic levels. and the use of a modified-release formulation 
ensures treatment over a sufficiently long period. An understanding of 
modified-release drug delivery systems is therefore important when 
developing such novel treatments for OME and biofilms. 
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2.5 MODIFIED RELEASE DRUG DELIVERY SYSTEMS 
As eradication of biofilms is likely to require high-dose locally-delivered 
antibiotics over a prolonged time period, the use of a modified-release drug 
delivery system may be one way of achieving that aim. Although modified-
release drug delivery systems have only been developed over the last few 
decades, they have resulted in great improvements in patient care. The 
increase in the use of modified-release drug delivery systems can be 
attributed to the major advantages they offer over conventional drug delivery 
(Anelli 2008) (Bajpai, et al. 2010) (Rosoff 1989) (Siepmann and Siepmann 
2008a), including: 
• Regulation of drug concentrations over a specific time period 
• Reduced administration frequency 
• Accessing sites of therapeutic interest that cannot be practically accessed 
using standard delivery (e.g. inside the blood brain barrier) 
• Drug targeting, with drugs being delivered only to the site where it is most 
needed 
• Pulsatile drug delivery, where drug is delivered at set time points, or 
pulsatile dosing with several drugs released at different lag periods 
(chronotherapeutics) 
• Potential for development of intelligent drug delivery systems that release 
drugs in response to a pre-defined biological event I parameter 
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2.5.1 Modified drug delivery systems 
To control the rate at which drugs are released (Siepmann and Siepmann 
2008a), the active ingredient may be embedded in a matrix of some type. 
Biodegradable polymers (large molecules composed of repeating structural 
units) are often used for this purpose. Three broad types of drug delivery 
systems are associated with biodegradable devices, shown in Fig 2.5.1.1, 
although in reality many devices' drug release is governed by a combination of 
factors. 
In diffusion-controlled systems the drug diffuses down a concentration 
gradient from the delivery device into the surrounding area. Different types of 
diffusion can be distinguished (Morishita and Park 2010): 
• Reservoir devices with a core-shell structure: Drug is at the centre of a 
shell, and diffuses through shell at a controlled rate (either with constant or 
non-constant activity) 
• Matrix or monolithic devices: Drug is distributed homogenously throughout 
the system 
• Laminated matrix devices contain a mix of matrix and reservoir devices 
with characteristics of both. 
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Fig 2.5.1.1: Schematic illustration of different patterns of drug release (Rosoff 
1989). 
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In all three cases the drug can exist in the system as a solution (drug 
molecularly distributed within system) or a dispersion. Matrix systems can be 
divided into those that are based on hydrophobic and those based on 
hydrophilic rate-controlling materials (Li and Jasti 2006). The hydrophobic 
systems keep their shape, with release of the active ingredient occurring by 
diffusion. The hydrophilic matrix devices swell in contact with an aqueous 
solution, with the control of release then affected by both diffusion and 
swelling, as well as matrix degradation (Ranade and Hollinger 2003). 
In swelling-controlled systems, drug release from the matrix occurs as the 
swelling front develops and moves into the release device. As the water 
reaches the inner core of the polymer matrix, drug is released into the 
aqueous phase and then to the surrounding fluid. In addition to matrix devices, 
hydrogels also release drugs in this way. Hydrogels are water-insoluble 
hydrophilic polymers that swell in water (Bajpai, et al. 2010), and the drug 
release from the hydrogel occurs when the drug comes into contact with the 
water front moving into the gel. 
Polymer swelling is also of importance, as it increases the length of the 
diffusion pathways, and therefore reduces drug concentration gradients and 
release rate. On the other hand, swelling can increase polymer molecular 
mobility and thus drug mobility, increasing the drug release rate. 
Erosion refers to the process of material loss from the polymer bulk, in 
contrast to polymer degradation that refers to a chain scission process by 
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which polymers are cleaved into oligomers and finally monomers. Erosion is 
classified into surface and bulk erosion. In surface erosion degradation occurs 
primarily in the outermost layers, so that as the surface polymer degrades the 
drug is freed; this results in a gradual shrinkage of the device and leads to 
erosion-controlled drug release. This surface erosion is distinct from bulk 
erosion, where the entire device is rapidly penetrated by water and thus 
polymer chains are cleaved throughout the system. Thus in bulk erosion the 
porosity increases, embedded molecules become more mobile and diffuse out 
of the system, the device outer dimensions stay the same until eventually the 
device disintegrates into smaller polymer fragments (Hausberger and Deluca 
1995). Polymers with very reactive functional groups degrade fast with surface 
erosion, whereas polymers with less reactive groups (such as PLGA) undergo 
bulk erosion. Thus surface erosion is like a bar of soap that gradually reduces 
in size, and erosion controls drug release, but bulk erosion is like a biscuit that 
crumbles when wet and drug release is governed by diffusion. Despite this 
classification, in reality the exact mode of erosion is affected by the balance 
between system wetting rate and polymer cleavage rate, the former also being 
affected by the dimensions of device (smaller devices are more readily wetted 
than larger ones) (von Burkersroda, Schedl and Gopferich 2002). 
In practice, several different mass transport phenomena concurrently affect 
drug release from modified-release systems (Siepmann and Siepmann 2008a) 
(Siepmann and Siepmann 2008b). In the case of PlGA systems, water 
penetration into the device is faster than polymer chain cleavage by ester 
hydrolysis and the system undergoes bulk erosion. This generates short chain 
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acids within the device, which diffuse out of the device into the surrounding 
fluid. Although bases can diffuse from the surrounding into the system to 
neutralise the short chain acids within the device, their diffusion can be 
relatively slow leading to a pH drop in the core of the device (Brunner, Mader 
and Gopferich 1999). This can accelerate polymer degradation and drug 
release, and may lead to undesirably rapid release of a dose of drug that was 
meant to be released over a slower time period (dose dumping) (Anelli 2008). 
Other factors affecting drug release (Li and Jasti 2006) (Morishita and Park 
2010) include solubility of drug in the device and surrounding medium, 
concentration gradient, drug loading, morphological characteristics such as 
porosity and surface area, hydrophilicity and hydrophobicity of the system, 
chemical interaction between drug and polymer, polymer characteristics such 
as molecular weight and glass transition temperature. For example, a high 
molecular weight drug will diffuse more slowly, binding effects will slow down 
the diffusion, a large molecular weight polymer will degrade more slowly, a 
hydrophobic polymer will absorb less water leading to less bulk degradation, 
and smaller more porous particles will have a greater total surface area with 
consequent faster diffusion of solvent into the particles and faster matrix 
degradation rate (Morishita and Park 2010). 
2.5.2 Biodegradable drug delivery systems 
Although drugs can be delivered in a controlled manner using non-
biodegradable vessels, biodegradable systems have significant advantages 
as the need for vessel removal is avoided (Bossy, et al. 2008) (Li and Jasti 
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2006). A variety of polymers can be used, including poly(amides), 
poly(esters), poly(orthoesters), poly(anhydrides) and others (Rosoff 1989). 
Poly(esters) particularly have been widely used, as they break down to 
naturally occurring substances, degradation only requires water, a wide 
variety of different properties can be obtained depending on monomers 
chosen, and early experience with suture materials means that a wealth of 
safety data already exists (Saltzman 2001). 
PLGA (Fig 2.5.2.1), a poly(ester) polymer has been the most widely studied 
biodegradable system (Bossy, et al. 2008) (Lu, et al. 2009), and has a long 
history of safe clinical use in sutures, implants, prosthetic devices, and depot 
drug delivery systems (e.g. Zoladex). It is biodegradable and biocompatible 
and approved by the US Food and Drug Administration. PLGA is synthesized 
by ring opening and co-polymerisation of two different monomers, lactic acid 
(C3HS03) and glycolic acid (C2H403), linked by an ester linkage. The result is a 
polymer, a large molecule composed of repeating structural units. The precise 
form is poly(DL-lactic acid-eo-glycolic acid), the DL showing that it is the 
racemic mixture of lactic acid (containing both stereoisomers). The polymer 
forms amorphous structures, glass-like with tangled chains (as opposed to 
ordered crystalline structures), and application of heat turns brittle solid 
material to a viscous liquid. Degradation involves hydrolysis in the presence of 
water, into monomers of lactic and glycolic acids, which are metabolised 
without any adverse reactions. Different forms of PLGA are characterised by 
different ratios of lactic to glycolic acids. 
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Fig 2.5.2.1: Poly(lactic-co-glycolic acid); x = number of units of lactic acid, y = 
number of units of glycolic acid. 
Drug release is typically triphasic, an initial burst due to release of drug on the 
surface and in the water channels, a second stage where drug is released by 
diffusion from the polymer, and a final burst as the polymer degrades 
(Yasukawa, et al. 2001). It is desirable for the second stage to exhibit zero 
order kinetics, where the amount of drug released from the device is 
independent of the amount of drug in the device, in other words an identical 
amount of drug is released during each time period (Bruck 1983). The general 
factors discussed above affect drug release, but there are also some issues 
specific to PLGA. Although the 50:50 form of PLGA has the fastest 
degradation time (about two months), generally a higher lactic acid content 
delays degradation, as does higher molecular weight. High drug loading may 
also increase release rate, but this may largely be due to the initial burst rather 
than sustained release. Blending different polymers can achieve drug delivery 
for up to a year whilst still remaining biodegradable (Kunou, et al. 2000). 
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PLGA can be used to form a matrix system with the drug dispersed between 
PLGA microparticles, or the drug can be encapsulated within each PLGA 
microsphere in the form of a suspension, liquid or solid (Fig 2.5.2.2). 
+++ 
+++ 
+++ 
Fig 2.5.2.2: Drug (red) can be dispersed between PLGA particles (blue), or 
encapsulated within PLGA 
Commercially available alternatives to PLGA (Lane, Okumu and 
Balausubramanian 2008) include microspheres and injectable gels, such as 
ReGel depot technology (PEG and PLG polymer) and the Atrigel drug delivery 
system. Biodegradable nanoparticles and liposomes can be injected 
intravenously with the intention of localising the drug to one particular area, 
but with these systems in addition to drug release itself, drug localisation and 
potential toxicity in non-target tissues also requires investigation. Modification 
of the drug itself can also enhance drug delivery (Ayoub, Wedemeyer and 
Wohr 2008), for example a pro-drug may be converted to active drug at site of 
interest, and addition of polyethylene glycol (PEG) to a drug (PEGylation, an 
FDA approved technology) increases its half life. PEG is eliminated by renal 
excretion . Delivery of a drug local to its intended site of action is a particularly 
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effective strategy, as often therapeutic effect can be achieved with minimal 
risk of systemic adverse reactions (Costantino, et al. 2007). The availability of 
injectable formulations that aggregate at body temperature has further 
expanded the potential applicability of novel drug delivery techniques 
(Fraylich, et al. 2008). 
2.5.3 Novel drug delivery to eradicate blofilms 
The application of novel drug delivery to the treatment of biofilms is a logical 
evolution for the multi-disciplinary translational researcher. Modification of 
implantable materials (Bayston, Ashraf and Bhundia 2004) (Bayston, Fisher 
and Weber 2009) (Biedlingmaier, Samaranayaki and Whelan 1998) (Furno, et 
al. 2004) or the use of ultrasound (Ensing, et al. 2006) (Huang, et al. 1996) or 
low-strength electrical fields (Blenkinsopp, Khoury and Costerton 1992) has 
already been mentioned, but the latter two techniques cannot be applied to 
the middle ear where neural structures and fluid filled cavities of the inner ear 
are in close proximity, nor is there access for photodynamic therapy. 
Eradication of biofilms is challenging (Lewis 2001 ), but biodegradable 
polymers may be a useful future strategy. 
Biodegradable polymers have been identified as a potential method of 
delivering antibiotics in a modified release manner (Cheow, Chang and 
Hadinoto 2010) (Coowanitwong, et al. 2008) (Smith 2005), with particular 
interest in the field of infected orthopaedic implants. However, within the 
middle ear, some studies of using modified drug delivery to eradicate middle 
ear infections have also been published. Goycoolea et al (M. Goycoolea, D. 
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Muchow, et al. 1991) (M. Goycoolea, D. Muchow, et al. 1992) (Goycoolea and 
Muchow 1994) studied modified release ampicillin from a poly-L-Iactic acid 
support in cat and chinchillas animal models, and found the method was 
effective at eradicating infection without any ototoxicity. Whilst encouraging, 
this is not a true representation of human OME, as animal models are either 
acute infections or Eustachian tube obstructions and no true animal model of 
OME exists. The important link with biofilms was also not investigated. 
Another study using pluronic F-127 to deliver vancomycin as a treatment of 
experimentally induced MRSA middle ear infection (Le, et al. 2004) is again 
encouraging but not a true representation of human OME. 
A major advantage of a modified release system to eradicate biofilms is the 
ability to place the device at the site of action. It has already been mentioned 
that biofilm eradication requires a locally high antibiotic dose, which would be 
difficult to achieve with systemic administration without major systemic toxiCity; 
the relationship between minimum effective concentration and minimum toxic 
concentration is described by the therapeutic window (Fig 2.5.3.1 ). 
Alternatives to placing antibiotics locally at site of action would be systemic 
administration of an agent that concentrates at a specific site, such as 
liposomes. These are composed of a phospholipid membrane surrounding an 
aqueous core that can hold therapeutic agents; they can be used to target 
drugs (Smith 2005) to phagocytes and the reticulo-endothelial system, but if 
coated with a surface antibody can be targeted to specific bacterial biofilms 
(Robinson, Creeth and Jones 2000). 
50 
Minimum Toxic Concentration 
Therapeutic Window 
Time 
Fig 2.5.3.1: Therapeutic window (Li and Jasti 2006). 
Advances in the field of drug delivery are likely to provide crucial new ways of 
eradicating biofilms. We chose to use a PLGA based monolithic device for the 
experiments on biofilm eradication as a novel treatment for OME, combined 
with a gel, either poloxamer (Fig 2.5.3.2) or carboxymethylcellulose (Fig 
2.5.3.3), plus rifampicin and clindamycin. The rationale for the choice of this 
modified release formulation, and its advantages and disadvantages, is 
discussed more in Chapter 11. 
CH3 
I 
H H2CH2 0 H2 H 'I 0 H2 H2 l OH 
Fig 2.5.3.2: Poloxamer (Sigma 2012) 
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Fig 2.5.3.3: Sodium carboxymethylcellulose (Sigma 2012). 
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2.6 SUMMARY 
Glue ear is an extremely common condition, with VTs insertion being one of 
the commonest surgical procedures. Whilst the recent NICE guidelines on the 
surgical management of OME have clarified best practice, it is not yet known 
whether they have had an impact on OME treatment, nor whether there is a 
variation in compliance across different hospitals. A great degree of 
controversy surrounds adjuvant adenoidectomy in conjunction with VTs to try 
and reduce the high rate of further surgery after VT extrusion, leading to the 
setting up of a multicentre UK study on glue ear treatment. The MRC Trial of 
Alternative Regimens on Glue ear Treatment (TARGET) examined children up 
to 2 years after randomisation to VTs, VTs+ad or watchful waiting, finding in 
favour of adjuvant adenoidectomy. However, with OME's chronic course, 
longer-term data is also of value, warranting supplementary studies beyond 
the TARGET 2 years. 
The aetiology of OME is unclear, but the role of bacteria and biofilms warrants 
further investigation using new methods that can demonstrate bacteria in the 
middle ear effusion. If OME is a biofilm infection, it is not surprising that VT 
insertion has such a high need for further surgery; VTs only remove the 
effusion, but do not deal with the underlying problem of a biofilm infection. A 
new treatment strategy based on better understanding of OME pathogenesis 
is therefore required. 
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In order to study OME biofilms and their eradication in the laboratory setting, a 
new in vitro model is required. Demonstration of biofilm structure as well as its 
functional characteristics, reduced susceptibility to antibiotics, will have to be 
demonstrated. High dose antibiotics delivered locally over several weeks are 
likely to be required for biofilm eradication, and the new model must be able to 
incorporate the addition of antibiotics or a modified release device. Advances 
in the field of drug delivery are likely to provide crucial new ways of eradicating 
biofilms. 
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3 AIMS 
The thesis has two distinct parts: a collection of clinical studies, and series of 
laboratory experiments. The aims are as follows. 
CLINICAL STUDIES 
• Assess need for further surgery for OME after VT extrusion (TARGET trial 
long-term data) 
• Assess the impact of adjuvant adenoidectomy on need for repeat surgery 
(TARGET trial long-term data) 
• Assess practice in accordance with NICE guidelines on OME 
management, including whether they have changed our practice 
LABORATORY STUDIES 
• Consolidate existing microbiology data obtained by our group and 
establish presence of bacteria and biofilms in middle ear effusions 
• Develop an in vitro model to represent S aureus biofilm infection 
• Assess whether antibiotics (rifampicin and clindamycin) can be used to 
eradicate S aureus biofilms using the model 
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• Produce a biodegradable modified-release antibiotic pellet based on a 
PLGA matrix with rifampicin and clindamycin, and with either pluronic F127 
or carboxymethyl cellulose gels 
• Assess antibiotic release from the pellets with High Performance Liquid 
Chromatography (necessitating a new method) and Serial Plate Transfer 
Testing 
• Test the antibiotic pellets against biofilms in the in vitro model 
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4 THESIS OUTLINE 
The thesis is split into chapters that address specific questions. Each chapter 
contains a brief introduction summarising the important issues discussed in 
the main introduction (Chapter 2), a description of methods, followed by 
results and comprehensive discussion. 
The clinical chapters demonstrate that guidelines on OME treatment are not 
always followed, and that current OME treatments have major shortcomings, 
with many children requiring VT surgery more than once. Additional 
adenoidectomy may improve on this, but the rate of recurrence remains high. 
Thus there is a clear need to develop better treatments, and better 
understanding of OME aetiology is key to developing new therapeutic 
strategies. Therefore, the role of bacteria and biofilms in OME is investigated 
next, demonstrating the important role that these play in the 
aetiopathogenesis of OME. 
In order to study the treatment of biofilms, an in vitro S aureus biofilm model is 
developed next, and used to test whether rifampicin and clindamycin can be 
used to eradicate biofilms. Demonstrating that they can, a modified-release 
antibiotic PLGA-based formulation is then developed. Drug release from these 
antibiotic pellets is investigated with High Performance Liquid 
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Chromatography and Serial Plate Transfer Testing, and the pellets tested in 
the in vitro biofilm model showing that they are capable of eradicating biofilms. 
Overall, the thesis shows that current treatment has significant shortcomings, 
but better understanding of OME aetiopathogenesis opens up the possibility of 
improved treatment. Although further development is required, antibiotic 
pellets may be a useful, better future treatment for OME. 
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5 CURRENT OME TREATMENT: VENTILATIONS TUBES AND 
THE BENEFITS OF ADENOIDECTOMY 
5.1 INTRODUCTION 
Examination of the effectiveness of current OME treatment is the starting point 
for this thesis, underpinning the need for further investigation into OME 
aetiology and the development of improved treatment based on better 
understanding of OME pathogenesis. As described in the introduction, current 
treatment guided by NICE is Ventilation Tube (VT) insertion. However, about a 
quarter of children are thought to require further surgical treatment, although 
adenoidectomy may reduce this (Gates, Avery and Prihoda 1987) (Kadhim, et 
al. 2007) (Maw and Bawden 1994) (Popova, Varbanova and Popov 2011) 
(Rosenfeldt and Bluestone 1999). 
The UK Trial of Alternative Regimens in Glue Ear Treatment (TARGET) set 
out to determine how effective VTs were and what was the role of adjuvant 
adenoidectomy. TARGET was a multicentre trial, examining children up to 2 
years after randomisation to VTs, VTs and adenoidectomy (VTs+ad) or further 
watchful waiting (the term further was used because all children had already 
undergone a three month observation period prior to randomisation). There 
were also some children in whom symptoms were deemed so severe that 
withholding surgery would be unethical (termed obliged to treat, OTT), and 
these were listed straight for surgery, with the type of surgery allocated being 
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chosen by the clinician on the basis of need; these children were included in 
the final analysis together with the randomised ones to boost patient numbers. 
VTs were shown to benefit hearing, but only for as long as they stay in place 
(Browning 2012) (MRC Multicentre Otitis Media Study Group 2001a) (MRC 
Multicentre Otitis Media Study Group 2001 b). Once VTs extruded, those 
children treated with VTs had hearing that was the same as the children 
receiving no surgery; a variety of reasons was responsible for this lack of a 
benefit of VTs at 2 years, including the fact that in the VT group hearing again 
deteriorated after VT extrusion, in the further watchful waiting group hearing 
improves over time in keeping with natural history of OME, and also because 
62% of the group randomised to further watchful waiting actually switched to 
receive surgery within a year (thus diminishing benefits of surgery if analysis 
on intention to treat basis is performed; further watchful waiting was 
incorporated into TARGET to determine if surgery could be avoided 
altogether, but the high switching rate from observation to surgery confirms 
parental and clinician beliefs that surgery is required and effective). 
In contrast, adjuvant adenoidectomy benefits hearing for the full 2 year 
duration of the trial, so that even after VTs have extruded the children that had 
VTs+ad still have better hearing than those receiving no surgery (Fig 5.1.1). 
60 
40 
35 
-...J 
% 
Z 30 CD 
~ ~
-a; 
> 25 CD 
en 
c 
-.: 20 IV CD 
% 
15 
10 
0 3 
TARGET: Hearing level results over 2-year period 
Controls 
(FWW) 
6 9 12 
VTs+ad 
15 18 
TIme since randomisation (months) 
-2.... FWN 
-0- VTs 
~ ~ VTs+ad 
21 24 27 
Fig 5.1 .1: Hearing results from TARGET (Courtesy of Mark Haggard). showing 
that hearing improves in further watchful waiting group, but deteriorates 12 
months after VTs so that the hearing loss in the two groups at 12 months is 
comparable. In contrast, children receiving VTs+ad have better hearing at 24 
months that either of the two other groups. 
TARGET only examined children over a two year period. However, as already 
detailed in the introduction, the natural history of OME often spans years, with 
20-25% thought to need surgery more than once. Therefore, a follow-up 
period of more than 2 years post-surgery is clearly desirable. 
The work presented here therefore represents a longer follow-up period 
(minimum 7.5 years from randomisation) on a subset of TARGET children 
(those enrolled in Leicester), and examines need for revision surgery and 
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follow-up visits after VT insertion. The effect of adding adenoidectomy to VTs 
is also assessed; comparison is made between those children that had VTs 
alone and those that had VTs+ad, but because of high switching to surgery, 
the further watchful waiting group is not analysed as a group in its own right. 
In addition to examining current outcomes, this chapter comments on the 
appropriate time scale for evaluation of treatment in a potential future clinical 
trial. 
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5.2 METHODS 
TARGET, the Trial of Alternative Regimens in Glue Ear Treatment has been 
described above, and its structure and patient flow are shown in Fig 5.2.1 and 
5.2.2, respectively. Children aged 3.5 to 7 years, with a hearing level of 20 dB 
NHL or worse, and tympanometry indicative of middle ear fluid (B on both 
sides, or B on one side and C2 on the other), were included. The "obliged to 
treat" children were included with the randomised ones to boost numbers for 
analysis, with work by TARGET team confirming validity of this strategy 
instead of analysis by intention to treat, because both analysis strategies yield 
very similar results; the combined analysis was termed "as allocated" as it was 
performed on the basis of a treatment that the child was allocated rather than 
randomised to. 
In addition to short (2 years) scheduled trial follow-up, TARGET obtained 
outcomes in an adjunct study after visit 7 (post visit 7, PV7, study) that 
examined the need for further treatment after the scheduled two years of the 
initial trial. However, the PV7 length of follow-up was 1.2-5.5 years after trial 
exit, meaning that the follow-up in some cases was as short as 3 years and 3 
months from randomisation. Therefore, an additional way of assessing long 
term outcomes was required. The original TARGET data was collected by the 
TARGET multi-centre team, with my involvement dealing purely with this 
supplemental, long-term study shown in this thesis. 
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The data presented in this chapter encompass a further adjunct study, 
TARGET long term, which analysed consultations even beyond PV7 study, 
although only on a subset of patients. The minimum follow-up period was 7.5 
years from randomisation to the time of notes review taking place. TARGET 
long term study assessed effectiveness of VTs and VTs+ad by analysing the 
number of follow-up visits required and any need for further surgery. The 
notes of Leicester TARGET children were examined, and data on clinic visits 
and further surgery collated with existing information from the original two-year 
trial and the subsequent PV7 study. The TARGET team confirmed that 
Leicester children were representative of the whole TARGET group. 
Two different types of analysis were performed to compare VTs with VTs+ad. 
The first analysed children on the basis of what treatment they were allocated 
(encompassing the randomised children, as well as the obliged to treat ones). 
The second analysed children on the basis of what treatment they actually 
received, and thus contains a large number of children that were initially 
allocated further watchful waiting but switched to a surgical arm. Overall 
patient numbers are relatively small; for example, if one were to look for rates 
of repeat surgery to fall from 30 to 15%, a total of 124 patients in each group 
would be required to have 80% power to detect a significant difference at the 
0.05 level (using Lehr's formula). Statistical analysis was performed using 
SPSS PASW 18. 
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The following variables were examined: 
• Number of clinic visits at any time from randomisation 
• Number of clinic visits after the final planned trial visit at 2 years after 
randomisation 
• Number of OME-related surgical procedures at any time from 
randomisation 
• Number of OME-related surgical procedures after the final planned trial 
visit at 2 years after randomisation 
• Number of patients having OME-related surgery in addition to the 
treatment that they were allocated (in case of "as-allocated" analysis), 
• Number of patients having more than one procedure (in case of "as-
treated" analysis) 
• Length of clinical care, from randomisation to last clinical encounter 
• The percentage of patients visiting clinic after the trial end date 
• The percentage of patients having OME-related surgery after the trial 2 
years 
• The percentage of patients visiting clinic or having OME-related surgery 
after the trial 2 years 
Only OME-related additional procedures (VTs or other middle ear surgery, 
adenoidectomies) were counted. 
To assess how long any future trial should last, the number of visits made in 
each subsequent year after the end of the trial 2 years was examined. 
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5.3 RESULTS 
Of the 432 randomised plus obliged to treat children in TARGET, 102 were 
enrolled in Leicester (almost one quarter of the total): 93 randomised and 9 
obliged to treat. Medical records of 98 children were available for analysis. 
The minimum follow-up period from randomisation was 7.5 years, ranging up 
to 11.6 years. 
Table 5.3.1 shows the outcomes when patients were analysed on the basis of 
what treatment they were allocated (encompassing those that were 
randomised plus obliged to treat children). Table 5.3.2 compares outcomes 
when analysis was performed on the basis of what the patient actually 
received (and thus contains additional switchers from further watchful waiting 
to surgery). 
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ANALYSIS: AS-ALLOCATED VTs VTs+ad p 
(N=33) (N=35) 
CLINIC VISITS 
Mean N of visits at any time (SO) 9.58(5.62) 8.46(4.84) 0.381 
Mean N of visits after last trial visit (SO) 3.79(5.22) 2.57(4.05) 0.285 
SURGICAL PROCEOURES 
Mean N of procedures per patient at any time (SO) 2.27(1 .35) 1.66(1 .06) 0.040 
Mean N of procedures after last trial visit (SO) 0.85(1.09) 0.49(0.85) 0.131 
N (%) pts having procedures additional to allocation 21 (63.6) 16(45.7) 0.138 
LENGTH OF CARE 
Years (SO) 4.25(2.73) 3.62(2.69) 0.334 
NEEO FOR CARE AFTER LAST TRIAL VISIT 
N (%) of patients attending clinic 24(72.7) 18(51.4) 0.071 
N (%) of patients having surgery 18(54.5) 11(31.4) 0.054 
N (%) of patients attending clinic or surgery 24(72.7) 19(54.3) 0.115 
Table 5.3.1: TARGET Long Term outcomes, analysing patients on the basIs of 
allocated treatment. N: number. SO: standard deviation. P: p-value obtained 
using Chi squared test (comparing proportions) or t-test (comparing means) 
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ANAL YSIS: AS-TREATED VTs VTs+ad p 
(N=40) (N=46) 
CLINIC VISITS 
Mean N of visits at any time (SD) 9.90(5.40) 8.65(4.56) 0.250 
Mean N of visits after last trial visit (SD) 4.05(5.09) 2.70(3.85) 0.165 
SURGICAL PROCEDURES 
Mean N of procedures per patient at any time (SD) 2.23(1.31 ) 1.65(0.97) 0.023 
Mean N of procedures after last trial visit (SO) 0.88(1.09) 0.50(0.86) 0.079 
N (%) pts having more than one procedure 28(70.0) 27(58.7) 0.276 
LENGTH OF CARE 
Years (SD) 4.45(2.80) 3.73(2.61) 0.223 
NEED FOR CARE AFTER LAST TRIAL VISIT 
N (%) of patients attending clinic 30(75.0) 26(56.5) 0.073 
N (%) of patients having surgery 22(55.0) 15(32.6) 0.036 
N (%) of patients attending clinic or surgery 30(75.0) 27(58.7) 0.111 
Table 5.3.2: TARGET Long Term outcomes, analysing patients on the basIs of 
actual treatment received. N: number. SD: standard deviation. P: p-value 
obtained using Chi squared test (comparing proportions) or t-test (comparing 
means) 
The tables show that, whether analysed "as-allocated" or "as-treated", this 
group of children , entering TARGET with hearing loss of at least 20 dB NHL 
lasting at least 3 months, have significant healthcare needs during the trial 
and also afterwards. Patients allocated to VTs make nearly 4 clinic visits after 
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the trial ended, and their clinical care lasts on average 4.25 years from 
randomisation. Nearly three quarters needed to attend either clinic or have 
surgery even after the trial 2 years. 
In terms of need for revisions surgery, 63.6% of those allocated VTs end up 
having more surgery, and 70% of those receiving VTs as their first procedure 
have surgery again. Adenoidectomy does not significantly reduce need for 
revision surgery, but does appear to reduce the mean number of procedures 
(at any time) per patient, from 2.27 and 2.23 amongst those allocated and 
receiving VTs, respectively, to 1.66 and 1.65, respectively (p=0.040 and 
0.023). 
The number of visits made in each 6 month period following trial end is shown 
in Fig 5.3.1. Three quarters of children receiving VTs made clinic visits or 
needed surgery after trial 2 years, and it can be seen that the majority of visits 
after the 2 trial years happen within the first few years, as might be expected. 
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Fig 5.3.1: Total number of visits taking place during each 6 month period 
following TARGET 2 years. 
The number of visits (following the end of the 2 year trial) made by children of 
different ages is shown in Fig 5.3.2. The mean age of children making visits 
after trial ended was 9.4 years, range 6.0 to 17.0, with mode 7.0 and median 
9.0. After 11 years of age, the number of visits falls off, and more than 95% of 
visits have happened before 14 years of age. Fig 5.3.3 details the age at 
which last visit was made by each of the patients. The mean age at the last 
visit was 8.8 years, ranging from 4.4 to 17.1, with a mode of 13.0 years and 
median on 8 years. Majority of patients were aged 7-9 when they last made 
their ENT visit, and a further steep fall can be seen after 13 years. Taking 
these two last measures together, it would appear that by the time a child 
reaches 14 years , majority of OME-related disease appears to have resolved 
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5.4 DISCUSSION 
5.4.1 Summary of results 
The research presented here examined long term (> 7.5 years from 
randomisation) outcomes of VTs and VTs+ad, on a subset of children enrolled 
in the 2-year TARGET randomised controlled study of children with OME 
lasting at least 3 months and with a hearing loss of at least 20 dB NHL. 
Children allocated to VTs make on average nearly 4 clinic visits after the trial 
ended, their clinical care lasts on average 4.25 years from randomisation (and 
the time waiting for randomisation, initial ENT visit, and GP care on top) and 
nearly three quarters still needed to either attend clinic or have surgery even 
after the trial 2 years. Repeat surgery is necessary in 63.6% of those allocated 
VTs, and 70% of those that received VTs as their first treatment. 
Adenoidectomy did not significantly reduce need for revision surgery, but did 
reduce the mean number of procedures per patient from 2.27 to 1.66 (as-
allocated) and from 2.23 to 1.65 (as-treated). 
5.4.2 Choice of study population 
A major advantage of the TARGET clinical trial was that it studied the severely 
affected children that are being considered for surgery in modern UK practice; 
in fact, the TARGET entry criteria have now been broadly adopted by the 
NICE guidelines as the criteria defining eligibility for surgical treatment (NICE 
2008). Therefore, the TARGET children are the ones that have severe 
disease, and are representative of the kind of children that are treated in UK 
today. 
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The TARGET children also represent a much more severe population than 
has been studied by some other trials that may have included children with 
unilateral OME or OME of short duration, therefore representing a population 
of children in whom OME is likely to resolve soon anyway; for example, the 
Paradise trial that is often quoted as saying that VTs are "ineffective" included 
children with unilateral effusions or OME that is not continuously present for a 
minimum of 3 months, and in fact only 20% of the children studied had 
bilateral OME continuously for a minimum of 3 months (Paradise, et al. 2007). 
The fact that over half of those allocated in TARGET to a non-surgical arm 
switched to surgery supports the severity of OME in the population studied, as 
does the very high need for repeat surgery (63.6% in VTs and 45.7% in 
VTs+ad), and the high number of mean procedures per patient (2.27 and 
1.66, respectively). The use of short term ventilation tubes (Shepard tubes) in 
the trial is likely to be partly responsible for the high revision surgery rate; in 
addition, the longer one follows patients the more one sees need for repeat 
surgery, so that studies with> 2 years follow-up typically report much higher 
revision surgery rates (68% (Maw and Bawden 1994) and 36% (Kadhim, et al. 
2007» that are also seen in TARGET Long Term study. The fact that usual 
figures quoted for repeat surgery are 20-25% (Gates, Avery and Prihoda 
1987) again illustrates that TARGET studied a severely affected population 
and that long follow-up is imperative. 
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5.4.3 Choice of outcome measure 
Defining "success" of OME treatment is difficult. Hearing levels are easy to 
measure, but in themselves do not necessarily reflect the complex interaction 
between hearing, child's personality and abilities, environment, and adult 
input, all of which together influence a child's performance in their day to day 
activities, schooling and speech. Much research has looked at hearing levels 
because this is a quantitative variable that surgeons understand, but the 
"softer" outcomes have been less well studied. 
Looking at need for surgery or clinic visits as an outcome measure has distinct 
advantages. Both are determined by a composite that includes all the different 
variables that interact to affect how a child and parents deal with hearing loss, 
from the actual hearing level through fluctuation, intellect and social 
environment. However, such outcome measures are not objective like hearing 
levels or tympanograms, because they are influenced by parental and 
surgeon preferences; nevertheless, they are useful because they represent 
what happens in the real world. They are also very practical when exploring 
long term outcomes, as they simply record standard practice, and no 
additional investigations are required. For example, a child that is well is 
unlikely to wish to return for a hearing test 5 years after surgery because of 
trial requirements, but if they are no longer being seen in clinic it is reasonable 
to assume that they are having no or minimal problems. 
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However, a strategy based on hospital records follow-up does not take 
account of any care given in the community for example by the General 
Practitioners, and it also relies on people not visiting other hospitals or moving 
away. These concerns cannot be answered by our study, but it is unlikely that 
children randomised to one treatment are more likely to move away than 
those randomised to another arm, and only one hospital in Leicester provides 
ENT services. So, subject to reservations outlined above, looking at clinic 
visits and need for further surgery is a reasonable and practical way of 
examining long-term outcomes of OME treatment. 
5.4.4 Treatment with VTs 
TARGET showed that during the 2 years of the trial, VTs conferred a hearing 
benefit compared with no surgery. However, this was short lived, likely 
because hearing deteriorates once tubes extrude, those in no surgery group 
may spontaneously improve, and also the switching from further watchful 
waiting into surgery diminishes the benefits seen with VTs. In terms of 
hearing, at 2 years there is little difference between children randomised to 
VTs or no surgery. 
TARGET long term study assessed clinic visits and need for further surgery. 
In terms of clinic visits, any that occurred after the trial 2 years are more 
informative than those within 2 years, because the trial itself called for regular 
scheduled visits, but any attendances after 2 years represent genuine clinical 
need. 
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The results demonstrate that the clinical needs of children receiving VTs are 
substantial and stretch well beyond two years post randomisation. Analysing 
children as-treated shows that the mean number of visits was 9.9 (this also 
encompasses the 5 visits routinely planned as part of TARGET), but 75.0% of 
children still made clinic visits after trial ended, with the mean number of visits 
following trial end being 4.1. Also, 70.0% had to have surgery again, the mean 
number of procedures per patient was 2.2, and the mean length of care from 
randomisation to last recorded visit was 4.5 years. 
The need for further surgery in TARGET long term study appeared to be 
higher than the 20-25% rate reported in other studies (Gates, Avery and 
Prihoda 1987). As discussed above, a longer follow-up period picks up more 
children with on going problems, so that other studies looking at long term 
outcomes do typically report higher need for revision surgery, for example 36 -
68% (Kadhim, et al. 2007) (Maw and Bawden 1994). Additionally, the 
TARGET children represent a severely affected population and as such would 
be expected to have worse outcomes that the mildly affected children studied 
elsewhere (Paradise, et al. 2007). TARGET also used short term ventilation 
tubes (Shepard tubes), and although such tubes are less likely to lead to 
persistent perforation once tube extrudes, the fact that they only stay in for 6-9 
months or so means that many children remain troubled by OME once tubes 
extrude. 
The data on VT outcomes presented here is also in keeping with studies 
examining spontaneous OME resolution without surgery, which demonstrated 
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that, in children with bilateral OME that has already persisted for 3 months at 
the start of the study, OME has resolved in only a third of children 1-2 years 
later (Introduction Table 2.2.3.1) (Rosenfeldt and Bluestone 1999) (Maw and 
Bawden 1994). This is in keeping with TARGET's findings and the suggestion 
that VTs are a temporary management solution while waiting for OME to 
spontaneously resolve. 
Given the high need for repeat surgery following VTs, a treatment that would 
provide a more long-term or permanent solution for OME would be welcome. 
5.4.5 Adding adenoidectomy to VTs 
The TARGET 2 years had already shown that adenoidectomy in addition to 
VTs benefits hearing during and at the end of the trial 2 years. Adenoidectomy 
also appears beneficial later on as shown here, in terms of a reduction in the 
mean number of procedures per patient, although the magnitude of benefit 
(approximately 0.6 procedures per patient less with adenoidectomy) may not 
be large. Small patient numbers make meaningful statistical interpretation 
difficult when examining recurrence rates, and a larger patient group would be 
required to show a definitive benefit (or lack thereof). Adenoidectomy may 
also confer other benefits, for example less nasal obstruction, snoring and 
sleep apnoea, and sinusitis (Lieser and Derkay 2005) (Helfaer, et al. 1996), 
but these have not been studied here. 
One could argue that the reason that children allocated VTs alone end up 
having more procedures is simply because they still have the adenoid that 
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may end up being removed for non-OME reasons. However, all but one 
adenoidectomy in this study was performed in conjunction with ear surgery; 
one child had adenoidectomy together with tonsillectomy as a second 
procedure, but then ended up having revision adenoidectomy and VTs as a 
third procedure. Therefore, it cannot be said that adenoidectomies for non-
OME reasons form a significant number of cases. Additionally, because the 
study allowed the treatment of children on an "obliged to treat basis", any child 
with adenoid-related symptoms right at the start would not have been included 
in randomisation but instead would be in the obliged to treat group that ends 
up being analysed in the VTs+ad group. Whilst children may of course 
develop adenoid-related symptoms after randomisation, at least the ones with 
adenoid symptoms at the start are likely to have ended up with 
adenoidectomy as their primary treatment. 
Other research has also found adenoidectomy to be beneficial, as discussed 
in the main introduction, finding reduced time with effusion, reducing the mean 
number of tubes per patient, and a halving of the need for further surgery 
(Black, Sanderson, et al. 1990) (Gates, Avery and Prihoda 1987) (Kadhim, et 
al. 2007) (Maw and Bawden 1994) (NHS Centre for Reviews and 
Dissemination 1992) (Popova, Varbanova and Popov 2011) (van den 
Aardweg, Schilder, et al. 2010), although this has not been found universally 
(Casselbrant, Mandel, et al. 2009) (Dempster, Browning and Gatehouse 
1993). As discussed in main introduction, the likely reasons for 
adenoidectomy being beneficial to OME is the removal of nasopharyngeal 
biofilms that can act as a persistent focus for infection ascending the 
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Eustachian tube to the middle ear (Hoa, et al. 2010) (Kania, et al. 2008) 
(Nistico, et al. 2011) (Tonnaer, et al. 2005) (Winther, et al. 2009). 
Despite strong evidence in favour of adding adenoidectomy to VTs, this is not 
the recommended practice. UK guidelines (NICE 2008) advise that 
adenoidectomy should be performed if there are other, non-OME indications, 
whereas the US guidelines (R. Rosenfeld, et al. 2004) recommend it together 
with the second set of VTs. Because many children only have one set of 
tubes, subjecting all to adenoidectomy will expose many to unjustifiable 
additional surgical risks, and adenOidectomy itself does not prevent OME 
recurrence even if all children receive it. 
Thus, even with adjuvant adenoidectomy, the outcomes of OME treatment 
remain unsatisfactory, and 58.7% of those treated with VTs+ad still require 
further surgery according to this long term study in severely affected children. 
Any new strategy that may improve the high need for further surgery would be 
welcome. 
5.4.6 How long should any future OME trial last? 
Any randomised controlled trial faces the issue of appropriate time scale 
through which to evaluate a treatment, but in OME the timing issues are 
particularly challenging, because OME is a variably manifesting, fluctuating 
and eventually resolving condition. For most types of VTs an initial duration of 
up to 12 months is reasonable, as it is likely that tubes will have extruded by 
then. However, any trial needs to be sufficiently long to capture events after 
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VT extrusion and determine all benefits or risks. On the other hand, having too 
long a time-frame could be counterproductive, creating practical and resource 
problems in realising the trial, and setting up an unrealistic scale of lasting and 
large benefit against which an actual modest and short-term (though possibly 
worthwhile) result will appear insignificant. 
TARGET itself ran for 2 years, but the data presented here indicate that, 
although much important information can be obtained during 2 years, a 
significant number of children require care beyond 2 years. Differences 
beyond 7.5 years from randomisation (the minimum follow-up period in 
TARGET long term study) are less likely to be of interest, because by that 
stage children will be at least 11 years old (7.5 years from randomisation + 
minimum age 3.5 years at randomisation), beyond the age when OME 
resolves in many of children. However, longer follow up still could add more 
useful information, particularly as published data suggest that it takes 10 years 
before OME has resolved in 95% of children (Maw and Bawden 1994) 
(Rosenfeldt and Bluestone 1999). 
The current treatment of OME requires improvement to try and reduce the 
high recurrence rate. The data presented in subsequent chapters in this thesis 
suggests that using a modified release antibiotic formulation in the middle ear 
to treat biofilms associated with OME is a promising future therapeutic 
strategy. As such, at some stage a clinical trial will be planned to determine 
the effectiveness of this strategy. So what would be an appropriate time for 
trial duration? To some extent this is a subjective decision, but 2 years is 
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clearly not enough, and the trial should also extend beyond the 4.5 years that 
was the mean duration of care in children receiving VTs. A follow-up time of 
7.5 years from randomisation seems a sensible trial duration based on data 
presented here, although extending this to 10 years would be better still. 
Following up until a certain age is perhaps a better strategy (as it is known 
that OME does eventually resolve), and the data here support the notion of 
follow-up until a child is 14 years old. The trial duration recommendations 
made here seem sensible on the basis of presented data, but it has to be 
remembered that if one followed up children longer than in this study, 
additional visits at a later age could still become apparent. 
The duration of future trials may also be in part determined by the outcomes 
studied, and the ease with which the necessary data can be obtained. If one 
examines need for repeat surgery then a long term view if necessary, but 
insisting that all children irrespective of on going problems attend clinic is not. 
To study hearing, repeat attendances for audiometry would be necessary. If 
one studies the benefits that adenoidectomy has on nasal obstruction, then a 
2 month follow-up period is sufficient, at least initially, because surgery can be 
expected to have almost immediate benefit. If one studies acute otitis media, 
follow-up beyond 2 years of age can be limited, because most children grow 
out of the disease by that age. Medical records follow-up as in TARGET long 
term study appears to have been a successful, achievable, and affordable 
way of studying the outcomes of clinic visits and need for further surgery, 
whilst asking people to return to clinic or fill in questionnaires may have 
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received little uptake. A future clinical trial could therefore adopt a similar 
structure as TARGET and its long term follow-up studies. 
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5.5 TARGET LONG·TERM STUDY: CONCLUSION 
The recommended treatment for persistent OME, Ventilation Tube insertion, 
has significant shortcomings. Examining the long term (>7.5 years from 
randomisation) outcomes of VTs and VTs+ad, on a subset of children enrolled 
in the 2-year TARGET randomised controlled study of children with OME 
lasting at least 3 months and with a hearing loss of at least 20 dB NHL, 
demonstrates that the clinical care of children having VTs lasts on average 
4.25 years from randomisation, repeat surgery is necessary in 63.6% of those 
allocated VTs, and the average number of procedures per child is 2.27. 
Although adenoidectomy can reduce the mean number of procedures, the 
need for repeat surgery remains very high. The research presented here also 
demonstrates the importance of sufficiently long follow-up of children with 
OME to ensure that all their clinical care is captured. 
Current OME treatment therefore has significant shortcoming, and any new 
treatments based on thorough understanding of OME aetiopathogenesis could 
improve the care of countless children. Irrespective of their shortcomings, VTs 
are currently the only treatment recommended by NICE. But are clinicians 
actually following these recommendations? The next chapter examines 
whether children are being listed for surgery in accordance with NICE 
guidelines, and whether their recent introduction has changed practice. 
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6 ARE WE FOLLOWING NICE GUIDELINES ON THE 
MANAGEMENT OF OTITIS MEDIA WITH EFFUSION? 
6.1 INTRODUCTION 
Although OME is transient in the majority of children, a proportion develop 
persistent symptoms that may affect hearing, education, language or 
behaviour (Hall, Maw and Steer 2009) (NICE 2008). If OME persists after a 
three month period of watchful waiting, treatment with ventilation tubes (VTs, 
grommets) or hearing aids may be considered (NICE 2008) (Lous, et al. 
2005). With most UK parents opting for surgery, VT insertion is one of the 
commonest surgical procedures in children (Kubba, Pearson and Birchall 
2000), with over 30,000 inserted in England each year (HES 2010). 
The UK National Institute of Clinical Excellence (NICE) guidelines on surgical 
management of OME (NICE 2008) provide detailed guidance on the 
management of children younger than 12 years with suspected OME, 
covering history-taking, examination, and audiometric testing, and offering a 
review of the different management options. The guidelines, applied to "newly 
diagnosed OME of unknown duration", call for an initial 3 month period of 
observation, with repeat audiological assessment at the end of the three 
month period. At that stage, VT insertion should be considered for children 
with persistent bilateral OME with a hearing level in better ear of 25-30 dB 
NHL or worse (termed core criteria in this thesis), or for children not meeting 
87 
those audiometric criteria but when OME has significant impact on 
developmental, social or educational status (termed exceptional 
circumstances in this text). The guidelines state that surgery is not appropriate 
for children that have OME only for a short time period or in cases where OME 
has little effect on child's function and development. Adenoidectomy is not 
recommended in the absence of co-present history of frequent upper 
respiratory tract infection. 
We carried out a multi-centre comparison to establish whether children are 
being listed for surgery in accordance with NICE guidelines, and whether the 
guidelines have changed clinical practice. 
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6.2 METHODS 
A multi-centre retrospective case-notes review was undertaken, including all 
children aged 12 years or under having VT insertion before (Jul-Dec 06) and 
after (Jul-Dec 08) guideline publication in Feb 08. The units involved were 
Kings Mill Hospital Mansfield (Daniel, L Harrison), Queen's Medical Centre 
Nottingham (Daniel, Cho), Royal Derby Hospital (Daniel, Kamani, A Harrison), 
Royal Free Hospital London (Jaberoo, Yalamanchili) and Lincoln County 
Hospitals (EI-Shunnar). 
The guidelines were published in February 2008, and the study time period 
chosen therefore allowed over 4 months for guidelines' implementation, and 
all patients included would have been listed for surgery since guidelines 
publication. To establish whether guidelines had changed clinical practice, a 
six month period (keeping the time of year the same) prior to the introduction 
of the guidelines was also studied (1 st July to 31 st December 2006), applying 
the same NICE criteria retrospectively. 
All children aged less than 12 years having VT insertion were identified using 
the Hospital Information Support System data, and their medical records 
reviewed to identify those that had first VT insertion. Children with Down's 
syndrome or cleft lip I palate were excluded (NICE guidelines specify a 
different management pathway), as were those having surgery other than VTs 
alone or VTs with adenoidectomy, or those with major comorbidities, special 
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educational needs or other sensory impairment that may affect the decision to 
list for surgery. 
The medical records of the included children were studied to determine 
whether they were listed for surgery in accordance with NICE guidelines. The 
following variables were studied: 
• Did the child have two audiograms at least three months apart? 
• Did the child meet the audiological criteria of a hearing level of 25 dB NHl 
or worse (averaged at 0.5, 1, 2 and 4 kHz) in the better ear, at time of 
listing or at the pre-operative audiogram closest to surgery? 
• If both above criteria were met the child was deemed to have fulfilled 
guideline's core criteria. 
• Did the child have OME duration of at least 3 months on the basis of 
history, irrespective of whether the child had two audiograms or not? 
• When core criteria were not met, the clinical notes were reviewed to 
establish whether there was an extenuating reason for surgery, typically 
concerns over speech or schooling, or recurrent acute otitis media (AOM). 
The group of children that either met core criteria or had extenuating 
circumstances leading to surgery were deemed to have complied 
guideline's broad criteria. 
• What proportion of children complying with the broad criteria achieved this 
status due to extenuating circumstances? 
• Number of children having adenoidectomy was also examined, and we 
sought to establish whether adenoidectomy was performed purely for OME 
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or whether there was another reason in the notes that justified 
adenoidectomy. 
Statistical analysis was performed using SPSS Statistics 19. Differences in 
proportions were analysed using the Pearson Chi squared test or the Fisher's 
exact test if numbers were small. The Student's t test was used to assess 
differences in means. 
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6.3 RESULTS 
A total of 319 patients were included in the study. Notes of a further 41 
(11.4%) patients could not be obtained despite multiple searches at different 
times. The five different hospitals contributed 41, 90, 107, 30, and 51 patients, 
respectively. 
Pooled data from all 5 units were used to compare practice in accordance with 
the set criteria before and after guidelines were introduced. During the pre-
guidelines period there were 173 cases, and post-guidelines 146. In three 
units the number of VTs reduced, and in two increased after guidelines' 
introduction. The percentage of boys was 61.4% overall with no significant 
differences between the two time periods, and the mean age during both time 
periods was 4.7 years. 
Table 6.3.1 compares the two time periods. Practice in accordance with the 
core criteria has deteriorated by a significant amount (Chi squared p=0.032). 
However, there has been no deterioration in practice in accordance with 
guidelines if those children listed for extenuating circumstances were included, 
but this was achieved by a Significant rise in the number of such extenuating 
cases. A variety of extenuating reasons were noted, these are detailed in Fig 
6.3.2. 
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Variation between the five centres was also noted, for example the proportion 
meeting core criteria after guidelines publication ranged from 21.1 % to 39.5%, 
and the proportion meeting extenuating criteria from 84.2% to 91.3%, but this 
variation was not statistically significant. Additionally the centre that was least 
likely to meet core criteria had the most children with recurrent ADM (31.6%) 
and the centre most likely to meet core criteria had the smallest number of 
children with ADM (7.9%), so it is likely that variation in ADM rates in the local 
population may be responsible for at least some variation in listing practice. 
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CRITERION Pre-guldellnes Post-guldellnes Change pre- to 
(N=173) (N=146) post-guldelines 
2 audiograms ~ 3 3 months apart 100/173 80/146 !3.0% 
(57.8%) (54.8%) (p=0.589) 
Duration ~ 3 3 months 164/173 135/146 !2.3% 
(94.8%) (92.5%) (p=0.392) 
Hearing 25dB NHL or worse in 118/173 891146 ~ 7 . 2 % %
better ear (68.2%) (61.0%) (p=0.177) 
Fulfils core criteria 76/173 47/146 ~ ~ 11 .7% 
(43.9%) (32.2%) (p=0.032) 
Fulfils broad criteria 148/173 127/146 11 .5% 
(85.5%) (87.0%) (p=0.711) 
Exceptional cases proportion 72/148 79/127 t13.6% 
(48.6%) (62.2%) (p=0.024) 
Also had 37/173 29/146 ! 1.5% 
Adenoidectomy (21.4%) (19.9%) (p=0.738) 
Non-OME reason for 32/37 21/29 ~ 1 4 . 1 % %
adenoidectomy (86.5%) (72.4%) (p=0.154) 
Table 6.3.1: Practice In accordance with NICE gUidelines on OME dUring the 
two time periods. 
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REASON FOR EXTENUATING Pre-guidelines Post-guidelines 
SURGERY (N=72) (N=80) 
Speech problems 38 (52.8%) 46 (57.5%) 
Schooling problems 27 (37.5%) 25 (31.3%) 
Recurrent ADM 43 (59.7%) 26 (32.5%) 
Table 6.3.2: Reasons why children required surgery despite not meeting core 
criteria. 
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6.4 DISCUSSION 
6.4.1 Summary of findings 
Overall, 87.0% of children have VTs inserted in accordance with NICE 
guidelines in their broadest sense, although this relies on the inclusion of 
children meeting extenuating circumstances that justified VT insertion despite 
that child not fulfilling the core criteria. Only 32.2% of children met the core 
criteria of two audiograms 3 months apart with hearing level at 25dB NHL or 
worse, and this proportion appears to be lower now than it was prior to 
guidelines' publication. 
6.4.2 Practice in accordance with guidelines 
The aim of any guideline, a systematic statement of best evidence-based 
practice to assist doctors and patients in decision making about appropriate 
healthcare in specific circumstances (NHS Centre for Reviews and 
Dissemination 1994), is to inform and standardise best practice. However, 
whilst guidelines should lead to improved patient care, this is by no means 
universal (Freemantle, et al. 2000) (NHS Centre for Reviews and 
Dissemination 1994) (Oxman, et al. 1995). Much OME literature points to 
great variations in surgery rates and frequent non-compliance with existing 
guidelines. 
In Norway in 2002 the odds of surgery for OME or AOM varied 4 fold across 
different regions (Karevold, et al. 2007), and up to 10 fold for AOM across 
different countries (UK having the lowest rate) (Schilder, Lok and Rovers 
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2004). Within England, the number of VTs inserted (2007-2010) ranged from 
62.1 to 495.1 per 100,000 population (Child and Maternal Health Observatory 
2012), which does not seem to be any better than the seven fold variation 
between different districts reported in the 1980s (N. Black 1985). There was 
also a 10 fold variation in VT rates within Ontario in Canada in the late 1990s 
(Coyte, et al. 2001), this variation being larger than that seen in almost any 
other procedure. 
A US study in 2002 found that >90% of VTs were not inserted in accordance 
with guidelines in place at the time, and 81 % were not appropriate according 
to criteria developed by an expert panel for the study (Keyhani, et al. 2008). 
Even if children with other conditions that predispose to a poor developmental 
outcome, those requiring other surgery, or those that had previous VTs were 
excluded, the number of appropriate VTs was still less than 40%. The number 
of VTs in the UK was in the past considered excessive, and guidelines 
published in 1992 (NHS Centre for Reviews and Dissemination 1992) 
emphasised the fact that for many children OME was a temporary 
phenomenon and watchful waiting should be the norm for most. The rates of 
OME surgery in England halved during the 1990s, and although the guidelines 
undoubtedly contributed, there was already an existing downwards trend in 
surgery rates (Black and Hutchings 2002). The recent publication of NICE 
guidelines on the surgical management of OME does not appear to have 
affected rates of VT surgery in England and Wales (AI-Hussaini, Owens and 
Tomkinson 2011). 
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Several possible explanations exist for the variation in surgery rates, ranging 
from differences in clinical opinion on diagnosis and effectiveness of 
treatment, to parental preferences, and perhaps financial factors. Of course 
the problem may not be that surgeons are ignoring the guidelines, it may be 
that parents and health professionals feel that the guidelines are over-
restrictive and do not allow personalisation of care to each individual child. 
NICE guidelines do make provision for individualised care in those children 
that do not meet core criteria but in whom extenuating circumstances (such as 
schooling, speech problems or frequent infections) justify surgery. 
6.4.3 Duration of OME 
OME is a temporary phenomenon in most children. When discovered on 
screening of asymptomatic children, it resolves in 63% by three months and in 
88% by one year (Rosenfeldt and Bluestone 1999). The NICE guidelines have 
taken this into account, as treatment is inappropriate for most children with 
incidentally discovered, short-term, unilateral or asymptomatic OME. 
The group of children where surgery may be considered are those with 
bilateral OME persisting at least three months. This group has a much lower 
spontaneous resolution rate, only 32% by one year and 49% by three years 
(Rosenfeldt and Bluestone 1999) (Maw and Bawden 1994), with the median 
duration of OME being as long as 7.8 years (Maw and Bawden 1993). 
Although in this study only just over half of children had two audiograms three 
months apart, the proportion of children that had OME for three months or 
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more was in excess of 90%. This apparent discrepancy likely arises through a 
variety of reasons: in some younger children it may be difficult to obtain two 
audiograms, further waiting may be inappropriate for someone that has 
already had hearing loss for a year according to parents, and if a child has 
already developed speech or schooling problems at first presentation then 
delays for repeat audiometry may be inappropriate. 
6.4.4 Extenuating circumstances justifying surgery 
When faced with a child with OME and speech delay, schOOling problems, or 
recurrent infections, it is difficult to justify further delays for repeat audiometry 
in 3 months, or to not list a child for surgery if audiometric criteria are not met. 
Provision is therefore made for this in the NICE guidelines. Hence, when 
these extenuating cases are included with those meeting core criteria, the 
proportion of children having surgery in accordance with the guidelines in their 
broad sense rises to 87.0% in the post-NICE period, compared with only 
32.2% meeting the core criteria of 2 audiograms three months apart with 
hearing level of 25 dB NHL or worse in the better ear. 
Nevertheless, the high number of children having VTs due to extenuating 
reasons is surprising. As these cases should, by definition, be exceptional, the 
observation that they form 62.2% of all children meeting the broad NICE 
criteria suggests that they are almost the norm, rather than an exception. The 
proportion of children, amongst those meeting broadest listing criteria, that are 
having surgery due to extenuating reasons has also risen following guidelines 
introduction. This may suggest that surgeons are working within the 
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guidelines, following the suggested listing criteria, and documenting any 
reasons why surgery was recommended in a child that does not fulfil the core 
criteria themselves. 
6.4.5 Adenoidectomy 
As about 20-25% of children having VTs will require re-insertion of tubes 
within 2 years (Gates, Avery and Prihoda 1987), adenoidectomy as an adjunct 
to VT insertion has been investigated by several studies (Black, Sanderson, et 
al. 1990) (Browning 2012) (Casselbrant, Mandel, et al. 2009) (Dempster, 
Browning and Gatehouse 1993) (Gates, Avery and Prihoda 1987) (Maw and 
Bawden 1994) (MRC Multicentre Otitis Media Study Group 2001a) (MRC 
Multicentre Otitis Media Study Group 2001b) (Popova, Varbanova and Popov 
2010) (Rosenfeldt and Bluestone 1999). A 1992 review in Effective Health 
Care concluded that adding adenoidectomy to VTs had a small effect up to 12 
months post op (NHS Centre for Reviews and Dissemination 1992), whilst a 
Cochrane review in 2010 concluded that adenoidectomy has a significantly 
beneficial effect on OME resolution, although only a small benefit to hearing 
(van den Aardweg, Schilder, et al. 2010). 
In the UK adjuvant adenOidectomy is not recommended in the absence of 
persistent and/or frequent upper respiratory tract symptoms (NICE 2008). 
Whilst American guidelines agree with UK stance in the case of primary 
surgery, they recommend that adenoidectomy is undertaken in conjunction 
with any revision surgery (R. Rosenfeld, et al. 2004). The fact that most 
children do not require a second set of VTs is used to argue against 
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adenoidectomy at the first procedure. There is a great variation in the number 
of children receiving adenoidectomy in different countries, but on the whole 
the number of children having adenoidectomy appears to be reducing 
(Haapkyla, et al. 2008). 
This study examined adenoidectomy rates during two time periods, to 
establish if there has been a reduction in the number having adenoidectomy 
as a result of the guidelines advising against routine adenoidectomy in new 
cases of OME. There was no significant difference, suggesting that either 
most surgeons were either not performing adenoidectomy at the first 
procedure even before the guidelines, or that they are continuing to perform 
adenoidectomy despite the guidelines. The number of cases where 
adenoidectomy was justified for non-OME reasons fell after guidelines 
introduction (86.5 to 72.4%), but by a non significant amount. Thus, since the 
guidelines were introduced, in over a quarter of cases this study failed to find 
justification (within OME guidelines) for adenoidectomy taking place. As this 
was a retrospective case-notes review, it may well be that adenoidectomy was 
required, but the reasons why just not documented in the notes. Better 
documentation could be achieved in a prospective study, but this would not be 
appropriate when one is examining compliance with guidelines because 
clinicians' practice would likely be affected by the knowledge that they are 
being audited. 
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6.4.6 Limitations 
This study is limited by its retrospective nature. The documentation in patient's 
notes was used for the database, but at the time of the clinic visit there may 
have been other issues influencing a decision but not being documented. 
There were also a number of missing case notes, although there are no 
reasons to suspect that those children would be in any way systematically 
different. 
The study comprised 5 different units, ranging from small district general 
hospitals to large teaching hospitals. Although the results are representative of 
the overall practice in the five units studied, individual hospitals should 
undertake their own audits to assess local practice, as this study may not be 
representative of other individual units. 
The data here analysed only those children receiving surgery, and no 
comment can therefore be made on practice according to guidelines in those 
children that were never listed for surgery. Thus, it would be interesting to also 
examine whether surgery was being denied to children that may in fact have 
benefited from VTs. It would also be useful to examine if a longer time period 
for guidelines' implementation affected the results obtained here. and such a 
study is planned for the future. 
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6.5 NICE OME GUIDELINES: CONCLUSION 
This study shows that 87.0% of children have VTs inserted in accordance with 
NICE guidelines provided those children having extenuating reasons for 
surgery are included. However, only 32.2% meet the core criteria of 2 
audiograms three months apart with hearing level of 25 dB NHL or worse in 
the better ear, a significant number of children are having surgery due to the 
invoking of the exceptional circumstances criteria, and practice appears not to 
have changed. Individual hospitals should ensure continued practice within 
guidelines and improvements by means of regular departmental audit. 
This chapter is the final clinical one, as the remainder (and main part) of the 
thesis explores laboratory aspects of OME, biofilms, and potential new 
treatments. The clinical chapters, showing that current treatment with VTs 
carries a high need for revision surgery that is only partially improved by 
adenoidectomy, and that clinical guidelines on OME management are 
frequently ignored, provide clear supporting evidence for the need to better 
elucidate the aetiology of OME and develop improved treatments based on 
better understanding of OME aetiopathogenesis. 
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7 BACTERIA IN OME 
7.1 INTRODUCTION 
Although OME is an extremely common condition, much discussion has taken 
place regarding its aetiology (Rovers, et al. 2004). OME is a chronic 
inflammatory condition, with the inflamed mucosa producing mucus that 
accumulates in the middle ear cleft (Kubba, Pearson and Birchall 2000). 
However, the cause of this inflammatory response has been controversial. 
Much attention has focussed on bacteria in OME, but standard culture 
techniques typically grow bacteria in less than half of effusion samples (Matar, 
et al. 1998) (Hall-Stoodley, Hu, et al. 2006) (Schousboe, et al. 2001) (Gok, et 
al. 2001) (Poetker, et al. 2005) (Bluestone, Stephenson and Martin 1992) 
(Hendolin, et al. 1997). On the other hand, PCR can detect bacteria typically 
in more than 80% of effusions (Kubba, Pearson and Birchall 2000) (Hendolin, 
et al. 1997) (Post, et al. 1995) (Rayner, et al. 1998). The problem with peR is 
that detection of bacterial DNA does not imply the presence of live bacteria, 
and it has also been shown that components of the middle ear effusion 
actually inhibit nuclease activity and thus nucleic acid degradation (Peizhong, 
et al. 2000). 
The investigations of biofilms as causative agents OME has arisen from the 
PCR / culture discrepancy, because biofilm bacteria may be slow-growing and 
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difficult to culture in the laboratory, and the localised nature of biofilm 
communities may make effusion sampling prone to errors and false negative 
results. Further, the chronic nature of OME, its inflammatory histology in the 
absence of symptoms and signs of acute infection, and failure of oral 
antibiotics to confer a lasting benefit would be considered typical of a biofilm 
infection. 
The aim of this section therefore is to investigate the role of bacteria and 
biofilms in OME. Effusion samples were cultured for a prolonged period of 
time on a wide range of media, with the intention of capturing all possible 
bacteria involved in OME. The effusion samples were also analysed using the 
Live Dead stain with the intention of identifying live bacteria without the need to 
grow them in the laboratory, and also to determine whether those bacteria 
existed in biofilm morphology. 
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7.2 METHODS 
7.2.1 Clinical details 
The study was approved by Nottingham Research Ethics Committee, and 
informed consent obtained from participants and parents/carers. Patients were 
recruited in a large teaching hospital (Nottingham University Queen's Medical 
Centre), with samples collected between May 2006 and January 2008, and 
analysed during that time and over the subsequent 2.5 years. Patients were 
listed for ventilation tube insertion according to standard clinical practice, due 
to symptomatic OME perSisting for at least 3 months. The deliberately wide 
inclusion criteria were chosen to maximise the applicability of study results to 
clinical practice. 
The ear canal was disinfected by instilling 70% isopropanol for 2 minutes, with 
external ear canal swabs performed before and after alcohol disinfection. 
Myringotomy was performed using standard aseptic technique, and effusion 
aspirated into a sterile collection tube and transported for immediate 
processing. 
7.2.2 Bacterial culture 
To identify bacteria in effusion samples, the samples were analysed in a 
dedicated microbiology laboratory routinely involved in the processing of 
clinical samples. Effusion samples were cultured on six different media with 
the intention to capture as many different bacteria as possible. Sheep blood 
and MacConkey agar plates (Oxoid, Basingstoke, UK) were incubated 
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aerobically for up to three weeks at 37°C. The remaining four media 
(Helicobacter pylori, chocolatised blood for Haemophilus influenzae, and 
Mycoplasma selective agars incubated in 5% CO2, and sheep blood agar 
incubated anaerobically), were incubated for up to ten weeks. 
7.2.3 Bacterial identification 
Bacteria were identified using conventional tests including Gram stain, 
catalase, oxidase and DNase production, optochin susceptibility, response to 
growth factors X (hemin) and V (nicotinamide adenine dinucleotide), and 
growth in anaerobic conditions. Analytical Profile Index (API) strips 
(bioMerieux, Marcy l'Etoile, France) were used to aid identification and 
speciate the isolates. 
7.2.4 LiveDead stain 
The Live Dead stain (Molecular Probes, Oregon, USA) was used according to 
the product literature protocol, by combining an equal amount of sample with 
the stain solution, mixing thoroughly, and incubating in the dark prior to 
examination with appropriate fluorescence filters. The Live Dead stain employs 
differential membrane permeability to stain intact and uncompromised 
bacterial cell membranes (Le. live bacteria) green with SYTO 9, whereas 
nuclei of dead bacteria stain red with propidium iodide. Eukaryotic-derived 
material also has a tendency to stain red. 
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7.2.5 Confocal microscopy 
Combining the Live Dead stain with Confocal Laser Scanning Microscopy 
(CLSM) allows the determination of the three dimensional structure typical of 
biofilms. CLSM was performed using a Leica SP2 microscope (Leica, Milton 
Keynes UK), on samples stained with the LiveDead stain. Biofilms were 
diagnosed on the basis of well-established morphologic criteria (Parsek and 
Singh 2003) that have been applied to OME in the past (Hall-Stoodley, Hu, et 
al. 2006), i.e. the presence of three-dimensional bacterial clusters within an 
amorphous matrix and associated with a surface such as eukaryotic cells or 
strands. 
Two assessors (myself and Roger Bayston) determined bacterial morphology, 
and both were blinded to the culture result; in case of discrepancies, John 
Birchall also reviewed the images and a consensus between the three 
reviewers reached. 
7.2.6 Statistical analysisStatistical analysis was performed using PASW 
Statistics 18. Differences in proportions were analysed with Chi squared test, 
or the Fisher's exact test if numbers were small. The Student's t test was used 
to assess differences in means. Cohen's Kappa coefficient was used to 
measure agreement between different variables attached to the same sample. 
John Birchall and his theatre team collected the clinical samples. Shehla 
Imtiaz-Umer performed majority of routine microbiology work, with myself 
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performing the remainder, in addition to collating and analysing data, and 
performing statistical analysis. 
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7.3 RESULTS 
A total of 62 samples from 42 different patients (27 male, 15 female) were 
analysed. Most patients (35, 83.3%) were aged under 18 years, the median 
age being 4.5 years and age ranging from 1 to 75. 
7.3.1 Verification of canal disinfection 
A random subset of 14 ears was analysed to assess effectiveness of alcohol 
disinfection, by comparing culture results in external ear canal swabs taken 
before and after disinfection. Four swabs were culture positive prior to 
disinfection (one containing Streptococcus constelatus, one Bacillus spp, and 
two coagulase negative staphylococci). All swab cultures were negative after 
d isi nfection. 
7.3.2 Effusion culture and confocal microscopy 
Twenty-eight of the 62 effusions were culture-positive (45.2%), but CLSM 
demonstrated live bacteria in 51 (82.3%) samples. Table 7.3.2.1 illustrates the 
relationship between culture and CLSM results, showing that only 8.1 % of 
samples were negative on both examinations. In other words, combining the 
two techniques identified the presence of live bacteria in 57 effusions or 
91.9%. 
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CLSM-positlve CLSM-negatlve Total 
Culture-positive 22 (35.5%) 6 (9.7%) 28 (45.2%) 
Culture-negatlve 29 (85.3%) 5 (8.1%) 34 (54.8%) 
Total 51 (82.3%) 11 (17.7%) 62 
Table 7.3.2.1: Comparison of culture and confocal microscopy results; 
percentages refer to the per cent out of all 62 samples. 
Among the CLSM-positive samples, 25 (49.0%) contained biofilms and 26 
(51.0%) planktonic bacteria. Culture positivity appeared not to influence 
bacterial morphology at CLSM, as the proportion of samples exhibiting biofilm 
morphology was similar in the culture-positive and culture-negative groups 
(11/22, 50.0% and 14/29,48.3%, respectively). 
Differences between adults and children were explored on a per-patient 
(rather than per-ear) basis; where data existed for two ears, the per-patient 
analysis was carried out using the criteria of at least one ear being culture / 
confocal positive and at least one ear containing biofilms. Children appeared 
to have a greater number of culture-positive, confocal-positive, and biofilm 
results than adults (54.3 v 14.3%, 82.9 versus 57.1 %, and 67.9 v 0%, 
respectively). However, only the presence of biofilms reached statistical 
significance (Fisher's exact test p=0.02). 
In the 20 patients (all children) in whom data from both ears were available the 
correlation between the findings in the two ears was assessed. The 
agreement rate was 70.0% (14/20) in the case of culture positivity rate 
(kappa=0.381, fair agreement), 90.0% (18/20) in the case of confocal positivity 
I I I 
rate (kappa=0.444, moderate agreement), and 58.8% (1 0/17 confocal positive 
samples) in the case of confocal morphology type (kappa=0.168, poor 
agreement). The same bacteria were identified in both ears in 7 children 
(35.0%) 
Table 7.3.2.2 shows the range of different bacterial isolates, including the 
relationship of bacterial isolates to CLSM findings. The mean number of 
different bacterial isolates was 1.8 per culture-positive sample, with no 
significant difference between confocal-positive and confocal-negative 
samples. Biofilm samples contained an average of 1.7 and planktonic samples 
2.0 different bacterial isolates, but this was not statistically significant on Hest 
(p=0.51). Only one adult patient's effusion was culture positive, growing S 
capitis and Acinetobacter radioresistens, with most bacteria identified thus 
coming from children's effusions. 
Figure 7.3.2.1 shows representative images obtained with CLSM. 
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Culture results Confocal microscopy 
BACTERIA N (%) isolates Negative Positive 
among all 62 I· 
II 
samples Biofilm Planktonic 
CoNS 8 (12.9) 1 7 2 5 
Veillonella spp 6 (9.7) 3 3 3 
Staphylococcus aureus 5 (8.1) 5 1 4 
Strap pneumonlae 4 (6.5) 1 3 2 1 
Bacillus spp 3 (4.8) 1 2 1 1 
Moraxella catarrhalls 3 (4.8) 1 2 1 1 
Pseudomonas spp 3 (4.8) 3 3 
Aclnetobacter spp 2 (3.2) 2 
Corynebact. propinquum 2 (3.2) 2 1 1 
Flav/monas oryzihabltans 2 (3.2) 2 2 
Haemophllus Influenza 2 (3 .2) 2 2 
Hel/cobacter pylori 2 (3.2) 2 1 1 
Vibrio metschnikovii 2 (3.2) 2 2 
Gemella haemolysans 1 (1 .6) 1 1 
Kocuria varians / rosea 1 (1 .6) 1 1 
Micrococcus sp 1 (1.6) 1 1 
Peptococcus sp 1 (1.6) 1 
Table 7.3.2.2: Different bacterial species isolated from effusion samples, and 
their relationship to confocal microscopy findings. Number (N) refers to 
number of isolates rather than number of samples. The coagulase-negative 
staphylococci (CoNS) isolates were 2 S. fugdunensis, 2 S. epidermidis, one 
each S. simulans, S. capitis and S. hominis, and one sample contained both 
s. capitis and S. lugdunensis. Acinetobacter consisted of one A. fwoftii and 
one A. radioresistens, and Pseudomonas consisted of one P. aeruginosa, one 
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P. stutzeri and one P. luteola isolates. Majority of bacteria were isolated from 
children's effusions, with only one adult patient's effusion being culture 
positive (containing S capitis and A radioresistens. 
Figure 7.3.2.1 (following pages) 
CLSM images showing live bacteria staining bright green, whereas dead 
bacteria and eukaryotic cells I material I DNA stain red. A: Copious live 
bacteria staining green, some as biofilm clusters associated with orange-
staining eukaryotic material (arrows), and some planktonic as single free 
bacteria (circled). B: Three dimensional representation of bacterial clusters 
(arrows) associated with red-staining eukaryotic material, plus planktonic 
bacteria (circled). C: Copious strands with biofilms (arrows) and planktonic 
bacteria (circled), with the same section represented three-dimensionally in D. 
E: Strands associated with biofilms plus planktonic bacteria, with the same 
section represented three-dimensionally in F. G: Clump of live bacteria 
staining bright green and some dead bacteria staining red, surrounded by an 
amorphous matrix staining dull green. H: Three-dimensional representation of 
bacteria (bright green) in an amorphous matrix (dull green) attached to red-
staining eukaryotic material. 
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7.4 DISCUSSION 
7.4.1 Summary of findings 
The results show that combining culture and confocal microscopy 
demonstrates live bacteria in more than 90% of OME samples, strongly 
suggesting a role for bacteria in the aetiopathogenesis of OME. Extended 
cultures alone were positive in 45.2%. However, CLSM was positive in 82.3%, 
and in these samples biofilms were demonstrated in 49.0%. A wide variety of 
different bacteria were also identified, rather than just the traditional three 
studied in the past (Streptococcus pneumoniae, Haemophilus influenza, 
Moraxella catarrhalis). 
7.4.2 Biofilms in OME 
The microbiology of OME has been studied for many decades, yet 
controversy still exists as to the role of bacteria in the aetiology of OME 
(Kubba, Pearson and Birchall 2000) (Parkinson, et al. 2006). A high proportion 
of effusions (typically more than half) are culture-negative (Matar, et al. 1998) 
(Gok, et al. 2001) (Schousboe, et al. 2001) (Poetker, et al. 2005) (Bluestone, 
Stephenson and Martin 1992). However, while PCR has demonstrated 
bacterial nucleic acids in a much greater number of patients (Hendolin, et al. 
1997) (Post, et al. 1995), nucleic acids identified at PCR may not represent 
viable bacteria. An alternative view of bacteria in OME is that they might be 
viable but not culturable by conventional means, a state that is commonly 
seen in biofilms (Proctor and von Humboldt 1998) (Proctor, et al. 2006). 
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Using CLSM we were able to detect biofilms in just under half of CLSM-
positive samples. However, CLSM identified live bacteria in 85.3% of the 
culture-negative samples. Among culture-negative samples 14.7% were also 
confocal-negative, but of the culture-positive samples 21.4% were confocal-
negative. This suggests that CLSM may under-estimate the presence of 
bacteria, perhaps due to sampling differences, as small samples of effusion 
must be further divided for each examination and bacteria may be very 
localised. There appeared to be no great difference between planktonic and 
biofilm bacteria identified on LCMS-positive samples, with similar numbers 
being culture-positive. Although one might expect all planktonic samples to be 
culture-positive, 16 planktonic effusions were culture-negative. It is possible 
that these bacteria did exist as biofilms (which may make them difficult to 
culture), but that original morphology was disturbed by the process of surgical 
aspiration or laboratory preparation/mixing. The fact that some effusions 
containing biofilms on confocal microscopy were culture positive is not 
surprising as bacteria from biofilms frequently leave the biofilm to enter the 
planktoniC state (and would therefore be culturable), and processing of 
samples for analysis may also disrupt the biofilm thus rendering the bacteria 
planktonic and then culture positive. 
Adults were included in this study to boost patient numbers. However, 
children's effusions appear to be more likely to contain biofilms than adults, in 
keeping with the expected infectious aetiology of OME in children but possibly 
a different aetiology in adults (Kubba, Pearson and Birchall 2000). In addition, 
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only one adult effusion was culture positive, again supporting the notion that 
paediatric OME aetiology is likely to be different to adult OME. 
No great correlation between findings in the opposite ears has been 
demonstrated, suggesting that individual ears may be subject to different local 
aetiopathogenic mechanisms. This is also in keeping with clinical findings that 
the two ears in a child often behave differently, and it is not uncommon to 
have unilateral OME. 
The question of whether OME is a biofilm infection has been addressed by 
Fergie et al (Fergie, et al. 2004). Parsek and Singh suggested that the 
following criteria should be fulfilled for a disease to be considered a biofilm 
infection (Parsek and Singh 2003): 
• Bacteria are adherent to substratum or a surface 
• Bacteria are living in cell clusters or micro-colonies encased in an 
extracellular matrix 
• Infection is generally confined to a particular location. 
• Infection is difficult or impossible to eradicate with antibiotics, despite the 
responsible bacteria being susceptible to the antibiotic when in the 
planktonic state. 
This study clearly demonstrated that the bacteria were alive (something that 
peR or DNA-based methods cannot do) in more than 90% of samples, 
biofilms were found in just under half of effusions. However, studies of middle 
ear mucosa (not effusions) have shown biofilms more frequently, perhaps in 
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65 - 92% of samples (Thornton, et al. 2011) (Hall-Stoodley, Hu, et al. 2006), 
whilst non-invasive in vivo optical techniques have demonstrated biofilms in all 
adults with OME but in none of the controls (Nguyen, Jung, et al. 2012). The 
seemingly higher biofilm presence in published literature does not necessarily 
contradict our findings as there are several reasons why a difference between 
mucosa and mucus may exist. It is possible that biofilms exist on the mucosa 
in most people with OME but exist within the effusion associated with mucins 
in only just under half of cases, or that biofilms on mucosa act as reservoirs of 
bacteria that then enter the effusion, or that there is an issue with which part of 
the effusion is sampled for analysis. The presence of an intact mucus layer 
appears to be important in controlling bacteria within the human gastro-
intestinal tract, as most bacteria reside on the luminal side of the mucus layer 
(van der Waaij, et al. 2005), with no direct contact with the epithelium unless 
inflammation is present (Swidsinski, et al. 2007) (Macfarlane and Dillon 2007). 
To the best of our knowledge we were the first group to assess middle ear 
effusions with Live Dead staining and confocal microscopy. A paper has been 
published since our work, but this analysed 4 children's effusions finding no 
biofilms (Hom0e, et al. 2009); with such a small number it is difficult to draw 
conclusions, especially as according to our data only half effusions contain 
biofilms. Another recent paper used fluorescence in-situ hybridisation, with 
species-specific probes, to look for biofilms in the effusion of children with 
OME of less than 3 months' duration, finding biofilms in 4 of 13 (30.8%) 
effusions (Chen, et al. 2012); effusions were centrifuged prior to analysis, 
which may have affected biofilm morphology. 
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But could biofilms be a part of the normal middle ear flora rather than the 
pathogenic cause of OME? While two studies did not find biofilms in mucosal 
biopsies of their healthy controls (Hall-Stoodley, Hu, et al. 2006) (Thornton, et 
al. 2011), another study (Tonnaer, et al. 2009) of middle ear mucosal biopsy 
at time of cochlear implant showed biofilms in 2 out of 45 cases without 
evidence of previous otologic problems or abnormalities, suggesting that 
biofilms may exist in the asymptomatic middle ear. The difficulty when 
researching biofilms in OME is choice of control group. Entirely normal 
patients do not require ear surgery, and all the control groups chosen are 
patients having surgery for another (ostensibly non-related) reason, but they 
cannot be considered to be normal. When studying effusions as in this study, 
the problem is compounded by the fact that the normal ear does not have an 
effusion, therefore no suitable negative control exists. An alternative might 
have been to study the mucus produced by normal middle ear mucosa, but 
this is produced in only minute quantities. It would be difficult to sample with 
anything other than a swab, and whilst culture would be possible, confocal 
microscopy of strands of actual mucus would not. Further, it also raises the 
ethical issues of taking samples from healthy people, as surgical access to the 
middle ear would be required. Even if one included patients having surgery for 
non-OME reasons, it is still an additional procedure not related to the 
treatment of that (control) patient, and the assumption that the patient having 
middle ear surgery is truly healthy and free from OME may be false. A further 
problem relates to the common phenomenon of temporary OME, so it possible 
that children considered "normal" may have biofilms in their middle ear 
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because they have a temporary problem that would never come to medical 
attention otherwise. 
Despite difficulty studying biofilms in OME, it is recognised that the presence 
of a biofilm (bacteria or bacterial products such as lipopolysaccharide) may 
lead to an inflammatory stimulus (Bemthal, et al. 2010) (Mittal, et al. 2009) 
(Foreman, Jervis-Bardy and Wormwald 2011), which may then result in 
middle ear mucosal inflammation via cytokine release, mucous cell 
hyperplasia, and ultimately clinical OME (Lin, et al. 2012) (Smirnova, et al. 
2002) (Schousboe, et al. 2001) (Stamer, et al. 2006). In chronic rhinosinusitis 
(Foreman, Jervis-Bardy and Wormwald 2011), another mucosal biofilm 
condition, the presence of biofilms was shown to be associated with alteration 
in host immune responses including those involving interferon gamma, 
granulocyte-colony stimulating factor, and macrophage inflammatory protein 
1-beta, with a local (not systemic) inflammatory response (Hekiert, et al. 
2009); biofilm presence has also been associated with marked destruction of 
the epithelial layer with complete absence of cilia, whereas those patients 
without biofilms either had normal mucosa or only partial mucosal damage 
(Galli, et al. 2008). 
It is also possible that different biofilms, perhaps at different times, in different 
positions, or when affected by different immune systems, lead to different 
pathological problems, in some cases contributing to disease and in others 
not; in the same way that different bacteria may give different diseases, 
different biofilms may give different pathology (Foreman, Jervis-Bardy and 
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Wormwald 2011). Biofilms may also act as a reservoir of bacteria, with some 
bacteria leaving the biofilm to become planktonic and disseminate. The 
observation of biofilms on ventilation tubes of children with chronic ear 
discharge suggests that the middle ear bacterial biofilms have at least the 
potential to be pathological (Barakate, et al. 2007), whilst the reduction in 
post-ventilation tube surgery ear discharge achieved through application of 
antibiotic drops at the time of surgery suggests that treatment directed against 
biofilms in middle ear disease may be possible (Thomas, Ojano-Dirain and 
Antonelli 2011) (Shinkwin, et al. 1996). 
7.4.3 Techniques and alternatives 
Biofilms were diagnosed on the basis of well-established morphologic criteria 
(Parsek and Singh 2003) that have been applied to OME in the past (Hall-
Stoodley, Hu, et al. 2006): three-dimensional bacterial clusters within an 
amorphous matrix and associated with a surface such as eukaryotic cells or 
mucus strands were classified as biofilms. In contrast, bacteria that appeared 
as individual bacteria rather than a grouping were considered planktonic, as 
were any bacterial groups that were not associated with a surface. Typical 
examples are shown in Fig 7.3.2.1. 
Although the BacLight stain enables differentiation only between bacteria with 
intact and damaged cytoplasmic membranes it is often used to differentiate 
between active and dead cells (Sachidanandham, Gin and Poh 2005) (O'Neill, 
et al. 2004), and while it appears to be accurate to consider membrane-
compromised bacterial cells as dead, the reverse (Le. intact membrane 
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signifies live cells) may not be true in a small number of cases (Berney, et al. 
2007). However, given that 82.3% of the samples in this study stained live on 
confocal microscopy, a small false-live rate will still leave the majority of 
samples as containing live bacteria. Combining the LiveDead stain with 
confocal microscopy was felt to be the best way of identifying any live but non-
culturable bacteria, and of determining the bacterial morphology to establish 
whether biofilms were present. 
peR has been used in the past (Kubba, Pearson and Birchall 2000) 
(Hendolin, et al. 1997) (Post, et al. 1995) (Rayner, et al. 1998), but it cannot 
differentiate between DNA from live and dead bacteria, even when the 
quantitative technique of real time PCR is used (Saukkoriipi, et al. 2002). 
Interestingly, a novel technique of differentiating whether DNA comes from live 
or dead bacteria has recently been developed (Kobayashi, et al. 2009). This 
uses the DNA-binding agent propidium monoazide to help identify DNA from 
live bacteria at PCR, and could be usefully applied to OME. 
Live Dead staining and confocal microscopy does not identify bacterial 
species. Therefore, Hall-Stoodley et al (Hall-Stoodley, Hu, et al. 2006) in their 
study on mucosal biopsies used Fluorescence In-Situ Hybridisation (FISH) to 
identify bacterial species. However, FISH identifies only those bacteria that 
are looked for with a species-specific probe, and would miss any that are not 
speCifically sought (unless one uses a pan-bacterial probe, but the 
identification then again becomes an issue). The adoption of a broad 
microbiological approach in this work, i.e. to aim to find any bacteria, rather 
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than designing experiments to find S pneumoniae, H influenzae and M 
cata"halis because that is what everyone else has found, is in fact a strength 
of this work. In relation to FISH, one could find only those bacteria that one 
looked for, and as our culture results identified 17 different bacteria that would 
mean running 17 different FISH experiments, and one would still miss 
identification of bacteria that we found in samples that were positive only by 
confocal microscopy and negative on culture. Interestingly, recent 
technological advances have combined PCR with mass spectrometry into 
automated technology that can detect a wide range of pathogens (Ibis T5000 
Universal Biosensor): although based on PCR with its associated limitations, 
this could be a useful technique in identification of bacteria in OME (Ecker, 
Drader and Gutierrez 2006). The future may also bring instruments that could 
visualise bacterial biofilms in situ in the middle ear, as new optical methods 
capable of detecting them are already being developed (Nguyen, et at. 2010) 
(Nguyen, Jung, et at. 2012). 
SEM has also often been used to identify biofilm. However, whilst biofilm 
identification on inert surfaces is usually straightforward, its usefulness on 
mucosal surfaces remains debatable due to difficulty differentiating biofilms 
from mucus. Therefore, confocal microscopy combined with the non-specific 
Live Dead stain or species-specific FISH is currently thought to be the gold 
standard method of identification of biofilms on mucosal surfaces (Foreman, 
Jervis-Bardy and Wormwald 2011 ). 
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7.4.4 Bacterial types in OME 
S. pneumoniae, M. catarrhalis and H. influenzae are the most common 
pathogens implicated in OME, and all are capable of forming biofilms (Starner, 
et al. 2006) (Hall-Stoodley and Stoodley 2009). However, rather than focusing 
just on those three bacteria, this study cultured effusions on a wide range of 
different media for prolonged time periods in order to capture as many isolates 
as possible. Interestingly, coagulase negative staphylococci (CoNS), 
Veillonella spp and S. aureus were the three commonest pathogens isolated 
in this study. CoNS were long thought to be non-pathogenic commensals, but 
with the recognition of their biofilm-forming capacity have emerged as the 
leading cause of biomaterials-related infection (McCann, Gilmore and Gorman 
2008) (Lyte, et al. 2003). They have also been previously implicated in otitis 
media (Bunse, et al. 1987), with one study finding CoNS in a third of effusions 
and a third of these isolates were of the slime-producing phenotype (Paluch-
01e5a, et a!. 2011). Veillonella is a Gram-negative anaerobe that inhabits the 
mouth and upper respiratory tract, forms biofilms (Palmer, Diaz and 
Kolenbrander 2006) and has previously been found in middle ear disease 
(Brook 1996). S. aureus also forms biofilms (Otto 2008) and has been 
identified in middle ear disease (Hyden, Akerlind and Peebo 2006). Although 
most of the bacteria in Table 2 have previously been isolated in middle ear 
disease, to the best of our knowledge Flavimonas oryzihabitans, Vibrio 
metschnikovii and Gemella haemolysans have not been implicated previously. 
This study found two effusions containing Helicobacter pylori. Some studies 
have suggested that H pylori is implicated in the aetiology of OME (Yilmaz, et 
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al. 2006), although others have not confirmed this (Ozcan, et al. 2009). 
Interestingly, bile acids and pepsin have also been found in the middle ear 
(Klokkenburg, et al. 2009) (He. et al. 2007), but whether they are important in 
the pathogenesis of OME is not clear. 
It is unclear why the present study identified the three traditional OME bacteria 
in a lower proportion of samples than other studies. Variation in prevalence of 
OME over time has been previously documented (Bluestone, Stephenson and 
Martin 1992), and may be due to patterns of antibiotic use or vaccination, 
particularly with the introduction of vaccines against H. influenzae type band 
s. pneumoniae. The adoption of a broad microbiological approach in this 
study with the aim of identification of all bacteria may also have detected 
species missed by studies adopting a narrower culturing approach. 
Although numbers of isolates of anyone bacterial species are small, it is 
interesting to note that majority of CoNS and S. aureus appeared in planktonic 
form, despite both being recognised as biofilm-forming pathogens (McCann, 
Gilmore and Gorman 2008) (Lyte, et al. 2003) (Otto 2008). Pseudomonas 
aeruginosa, which is well known to produce biofilms (Hall-Stoodley and 
Stoodley 2009). was also identified in biofilm morphology in this study, but 
Acinetobacter appeared difficult to identify on CLSM. 
7.4.5 OME biofllms in relation to OME natural resolution 
If biofilms cause OME. then why does OME resolve spontaneously in most 
children by the age of 10 years or so? And if biofilms cause OME. it may be 
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easy to understand why OME often recurs after VTs have extruded (VTs only 
masked the effusion but didn't treat the underiying biofilm), but why then does 
OME not always recur after VT extrusion? Why is every AOM episode not 
followed by OME? 
The last question is perhaps easiest to answer, as establishment of a biofilm 
will depend on the pathogenicity of the bacteria involved, and their interaction 
with the host immune response (Mittal, et a!. 2009). The host response may 
also be the reason why biofilm infections resolve. Younger children have more 
infections, perhaps due to relatively immature immune system, but perhaps 
also due to higher exposure to bacteria in communal areas such as school or 
nurseries. or exposure to bacteria encountered for the first time. However. the 
major immune maturations occur during the first two years of life (West 2002). 
hence it is difficult to see how immune maturation would cure glue ear in 3-7 
year olds. Environmental and behavioural changes can explain reduced 
infections in older children, but not the eradication of an established biofilm. 
Changes in the Eustachian tube may explain resolution of OME and biofilms. 
In children, the Eustachian tube is shorter, with the muscular attachments that 
normally open it being less favourable (Doyle and Swarts 2010). Hence. the 
mature tube will be less likely to allow reflux of nasopharyngeal contents into 
the middle ear, preventing infection in the first place, but the tube in an older 
child will also be opening and aerating the middle ear better. 
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The aeration of the middle ear may lead to drying of the biofilm and therefore 
its eradication. Certainly drying may be important as an adjunct to biofilm 
eradication for example following disinfection of a surface (Kovaleva, Degener 
and van der Mei 2010), but it appears not to be effective on its own (Wu, et al. 
2010) (Mordhorst, et al. 2009). However, aeration and drying may also have 
an effect on the middle ear mucosa itself. In the presence of inflammation, 
deficient ventilation, and high C02, the middle ear mucosa metaplases into 
numerous mucus-producing cells (Sade and Weissman 1977); the reverse 
may also be true, so that restoration of normal ventilation (either with VTs or 
by age-related improvements in Eustachian tube function) could reduce the 
number of mucus-producing cells and therefore lead to resolution of effusion. 
When discussing OME as a biofilm infection, the question that then arises is 
whether it really is the biofilms that caused the inflammation leading to the 
effusion in the first place, or did the effusion develop as a result of middle ear 
hypoventilation and the biofilms simply moved into the abundant mucus? It 
has already been stated in the introduction that OME cannot be caused simply 
by Eustachian obstruction (the effusion would then be a transudate, not an 
exudate), and the fact that effusions drain down the Eustachian tube almost 
immediately after VT insertion again suggests that the Eustachian tube was 
never blocked (Kubba, Pearson and Birchall 2000). Therefore, it seems 
unlikely that negative pressure as a result of Eustachian blockage is the 
initiating event; rather, the biofilms are likely to be responsible for the initial 
inflammatory insult leading to OME. Of course it may be possible that biofilms 
develop only in the presence of middle ear hypoventilation, or conversely that 
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Eustachian tube dysfunction arises because of the biofilm itself. It is 
interesting to note that in the case of the gastritis-causing Helicobacter pylori 
the presence of mucin actually inhibits biofilm production (Cole, et al. 2004), 
and in the case of lactobacilli the type of mucus affects the degree of adhesion 
(Li, et al. 2008). 
Although it seems likely that biofilms are responsible for initiating OME, 
improvements in aeration with age or VTs may be responsible for OME 
resolution. Hypoxia is known to have a potent pro-inflammatory effect on the 
respiratory epithelium (Steinke, Woodard and Borish 2008), whilst healthy 
middle ear mucosa permits bidirectional gas exchange between capillaries 
and the middle ear cavity (Ikarashi, Takahashi and Yamamoto 1999). It may 
be that better aeration improves the "health" of the mucosa and tips the 
balance away from biofilms and in favour of production of a smaller amount of 
less viscous mucous, which in tum may lead to biofilm clearance. 
7.4.6 Implications for glue ear management 
This study clearly implicates bacteria in the aetiopathogenesis of OME. 
Biofilms are likely to be important, as our study found them in 49.0% of 
confocal-positive effusions, and previous research has demonstrated them on 
more than 90% of mucosal biopsies in children with OME or recurrent AOM 
(Hall-Stoodley, Hu, et al. 2006). This new understanding of OME aetiology 
also leads to potential novel therapeutic possibilities that may improve the 
current management options. 
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At present, treatment of persistent symptomatic OME involves drainage of the 
effusion and VT insertion, but this does not address any persistent bacterial 
infection, and serves to merely remove the effusion that is the result of a 
middle ear inflammation. If the biofilm hypothesis is true, it is perhaps not 
surprising that more than a quarter of cases will require further surgical 
treatment (Chapter 5) (Gates, Avery and Prihoda 1987). A good way of 
confirming this would be to study microbiology of OME in children both at their 
first and also any subsequent treatment, for if biofilms persist then one may 
expect to find the same bacteria at second treatment. A literature search failed 
to find any papers comparing bacteriology at first and subsequent VT 
insertions, and at any rate the bacteria may be different simply because 
different bacteria have been acquired and replaced the original biofilm, or the 
same bacteria may be found at the second time not because they persisted in 
the middle ear but simply because they re-ascended from a colonised 
adenoid. 
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7.5 BACTERIA AND BIOFILMS IN OME: CONCLUSION 
The role of bacteria in OME has been controversial, with a long-held debate 
fuelled by the low number of effusions that are culture-positive and the 
controversy over whether PeR-positive samples indicate live bacteria. 
However, this study, using extended cultures and confocal microscopy, 
demonstrates live bacteria in more than 90% of middle ear effusions in 
children with glue ear, strongly suggesting that bacteria and biofilms are 
important in the pathogenesis of the condition. 
This understanding also opens avenues for potential new, better treatments 
for OME. Unlike planktonic bacteria, which would be expected to respond to 
conventional antibiotic treatment, bacteria in biofilms adopt a distinct 
phenotype with a slow growth rate that makes them recalcitrant to standard 
antibacterial therapy (Lewis 2001) (Hall-Stoodley and Stoodley 2009) 
(Sihorkar and Vyas 2001). Delivering high dose antibiotics directly to the 
middle ear is an interesting new strategy, and this thesis therefore moves on 
to look at biofilm eradication in the context of OME biofilms. 
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8 AN IN VITRO BIOFILM MODEL 
8.1 INTRODUCTION 
The observation that biofilms are implicated in the aetiology of OME opens an 
exciting avenue for potential novel treatments. As at present about 25% of 
children require grommet (ventilation tube, VT) insertion for a second time 
(Gates, Avery and Prihoda 1987) (Maw and Bawden 1994), and VTs 
themselves have been associated with problems such as tympanic membrane 
perforation and scarring (Daly, et al. 2003) (Le, Freeman and Fireman 1991) 
(Brown, Richards and Ambegaokar 1978) (Bonding and Tos 1985) (Maw and 
Bawden 1994), better treatment based on new understanding of the aetiology 
of OME is clearly required. Treatments aimed specifically at biofilms were 
therefore explored. 
We set out to develop an in vitro biofilm model that could be used to study 
biofilms and treatments directed against them. The test organism chosen for 
these experiments was Staphylococcus aureus. S aureus is a typical biofilm-
forming organism, it is robust, grows well as a biofilm, and is difficult to 
eradicate (Ojano-Dirain and Antonelli 2012). Although other bacteria (S 
pneumoniae, M catarrhalis and H influenzae) may be more frequently 
encountered in OME in published literature, they may also be more fragile in 
the laboratory setting than S aureus, and thus their absence at the end of an 
experiment may simply be a reflection of their fragility rather than an indication 
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of treatment success. Thus, S aureus was deemed a suitable starting point for 
investigating biofilm eradication with antibiotics. 
Whilst several in vitro biofilm models are available, an important consideration 
in our work on OME was to use a model with dimensions that are similar to 
the middle ear. Ultimately, we planned to test an antibiotic pellet for use in the 
middle ear, and thus the in vitro model would have to have dimensions that 
are comparable to the human middle ear. 
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8.2 METHODS 
The S aureus biofilms were established as detailed below. To use the models 
described as a model of biofilms, both physical and functional characteristics 
of biofilm need to be shown, with demonstration of reduced susceptibility to 
antibiotics essential (Donlan and Costerton 2002). Therefore the silicone discs 
were imaged using Scanning Electron Microscopy (SEM) and Confocal Laser 
Scanning Microscopy (CLSM), and the sensitivity to antibiotics of biofilm 
bacteria was compared with planktonic bacteria. 
To assess effect of treatment on biofilms grown on discs, the biofilms had to 
be removed from the substratum, and the bacteria re-suspended prior to 
plating onto agar. In order to ensure that only biofilm bacteria are counted, 
and not non-attached planktonic bacteria, the discs had to be rinsed carefully 
on removal. The model was therefore investigated with respect to the number 
of rinses required to remove non-attached bacteria, duration of sonication 
required to remove attached bacteria and whether sonication affected 
bacterial viability, effect of trypsin on bacterial detachment, and whether 
antibiotic solutions added to the models were effective for the duration of 
experiment. 
8.2.1 An in vitro biofilm model 
To study biofilm eradication an in vitro model was required, and set up as 
follows. Overnight cultures of Staphylococcus aureus (laboratory strains 
derived from OME) were sampled with an inoculation loop and suspended in 
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Tryptone Soya Broth (TSB) (Fig 8.2.1.1 and 8.2.1.2), to an optical density of 
0.08-0.13 (McFarland 0.5 equivalent) at 490nm measured using a Jenway 
Multicell Changer Spectrophotometer (Bibby Scientific Limited, Stone UK). 
The rifampicin and clindamycin MICs of the inoculum were established using 
the Etest strip (AB Biodisk, Solna, Sweden) on Iso-Sensitest agar (Oxoid, 
Cambridge UK). Silicone discs (Silicone elastomer, Goodfellow, Cambridge 
UK, 6.0mm diameter and 1.0mm thick) were placed into the solution, and 
incubated at 37°C, initially on an orbital shaker (Stuart orbital incubator S150, 
Jencons-PlS, lutterworth UK) for one hour and then static for one hour. The 
discs were rinsed three times in PBS prior to use. Clean control discs were 
prepared in an identical manner except that the TSB was not inoculated with 
bacteria (these controls were used so that any contamination of the models 
can be identified easily). The discs were then aseptically placed into a sterile 
bijoux bottle containing 2 ml TSB. The bijoux bottles were incubated at 37°C 
(Firlabo Incubator HPE, Firlabo, Meyzieu France). Planktonic bacteria were 
also investigated, by inoculating 20 ~ l l of bacterial suspension into the TSB in 
a bijoux bottle. 
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Silicone discs 
(6mm diameter 
1mm thick) 
S aureus from OME 
ovemight cultures , 
TSB 
Minimum Inhibitory 
Concentration test 
3r c 
1 hr rotatory shaker 
1 hr stil l 
Tryptone Soya Broth 
"""-__ Non-inoculated 
clean control discs 
Fig 8.2.1.1: Establish ing biofi lms for in vitro experiments 
Fig 8.2 .1.2: Silicone disc in TSB in a bijoux bottle. 
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8.2.2 Scanning electron microscopy 
For scanning electron microscopy (SEM), bacterial groupings were fixed in 
cold acetone for 1 hour and air-dried from tetramethylsilane, sputter coated 
with gold for 4 minutes, and examined with Jeol 6060LV variable pressure 
SEM (Jeol UK Ltd, Welwyn Garden City UK). Coating with a heavy metal 
ensures that the surface of the disc is electro conductive and does not 
accumulate electrostatic charge when bombarded by electrons, and it also 
enhances signal and surface resolution. 
As SEM requires sample dehydration (the SEM chamber is a vacuum as any 
gas would spread and attenuate the electron beam), it may result in significant 
distortion of the biofilm structure, and therefore some biofilm discs were also 
examined with Environmental Scanning Electron Microscopy (ESEM) which 
allows examination of whole hydrated biofilms, although with reduced 
resolution and visualisation of individual bacteria. Silicone discs were 
examined with Phillips XL30 ESEM-FED (FEI, Eindhoven Netherlands). 
8.2.3 Alcian blue stain 
The presence of extracellular matrix was examined using Alcian Blue (AB) 
stain. Biofilms were stained in situ on Phosphate buffered saline-rinsed discs, 
using Alcian Blue kit (HD Supplies, Aylesbury, UK) for 30 minutes, rinsed and 
examined using light microscopy (Nikon Eclipse TE200, Nikon Instruments 
Europe, Kingston UK). 
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8.2.4 Confocal microscopy 
Combining the Live Dead stain with Confocal Laser Scanning Microscopy 
(CLSM) allows the determination of the three dimensional structure typical of 
biofilms. CLSM was performed using a Leica SP2 microscope (Leica, Milton 
Keynes UK), on samples stained with the Live Dead stain. The Live Dead stain 
(Molecular Probes, Oregon, USA) was used according to the product literature 
protocol, by combining an equal amount of sample with the stain solution, 
mixing, and incubating in the dark prior to examination with appropriate 
fluorescence filters. 
The usefulness of the Live/Dead stain was also examined, by comparing 
results from the Live/Dead stain with culture results. As they both measure live 
bacteria, the results of the two tests may be expected to be very similar. A 
comparison between LiveDead stain and culture results was therefore 
undertaken, using pooled data from biofilm discs that were analysed during 
the study of the eradication of 1 and 5 day old S aureus (F2318) biofilms with 
antibiotic solution. Cohen's Kappa coefficient was used to measure agreement 
between different variables attached to the same biofilm grown in vitro, 
analysed using PASW Statistics 18. 
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8.3 RESULTS 
8.3.1 Demonstrating biofilm structure 
The biofilms were grown on roughened silicone discs (Fig 8.3.1 .1), as the 
rough surface provides easier attachment for biofilms than a smooth surface 
and therefore represent an environment favourable to biofilm formation 
(Almaguer-Flores, Ximenez-Fyvie and Rodil 2010). Although the presence of 
bacteria was often noted by the presence of a cloudy-appearing TSS (Fig 
8.3.1 .2), the presence of biofilms on the discs was examined using SEM, 
Environmental SEM (ESEM), confocal microscopy and Alcian blue 
polysaccharide staining . 
Fig 8.3.1.1: Light microscopy of the silicone disc (x1 000) 
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Fig 8.3.1.2: Cloudy appearance of the TSB indicating presence of bacteria (B), 
compared with an un-inoculated disc (C). 
The images from 1 day old biofilms of Staph aureus F2387 examined with 
SEM and ESEM , and from 5 day old biofilms examined using SEM, are shown 
in Figures 8.3.1 .3 and 8.3.1.4, respectively. Images of SEM from 5 day old 
biofilms of another S aureus strain , F2315, are shown in Fig 8.3.1.5. 
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Fig 8.3.1.3: One day old bacterial biofilms (S aureus F2387) seen with SEM 
(A-D; Jeol 6060LV variable pressure SEM) and with ESEM (E , F; Phillips 
XL30 ESEM-FED). 
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Fig 8.3.1.4: Five day old bacterial biofilms (S aureus F2387) seen with Jeol 
6060L V variable pressure SEM (8 to F). A: no bacteria control. 
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Fig 8.3.1.5: Bacterial biofilm (S aureus F2315) on day 5 seen with Jeol 
6060LV variable pressure SEM. 
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LCSM with Live Dead stain was also used to demonstrate the three-
dimensional nature of bacterial biofilms on silicone discs. Biofilms were either 
examined in situ on the disc, fixed on the disc, or the biofilm was scraped off 
the silicone disc and examined separately on a slide (Fig 8.3.1.6). 
Fig 8.3.1.6 (see images on following pages): LCSM showing S aureus (F2387) 
biofilms grown in vitro, stained with LiveDead stain. Live bacteria stain green, 
dead ones red. The irregular silicone disc surface also takes up stain giving 
rise to a stained background in those images that show biofilms in situ. The 
paired images show the maximum intensity projection first at the top of the 
page, followed by a gallery of images in the lower part of the page 
representing different sections through the biofilm. Within each is contained a 
set of three images, the top right showing green staining only, the top left red 
only, and the bottom right showing the green and red overlaid on the same 
picture. Day 1 biofilms scraped off a disc and seen embedded in a matrix (A -
max and B - gallery with O . 2 ~ m m steps). Fixed day 1 biofilm on disc showing 
bacteria that are dead (red) due to fixative (C - max, 0 - gallery with O . 2 ~ m m
steps). Silicone discs with day 1 biofilm (E - max, F - gallery with 1 ~ m m step 
size), and day 5 biofilms (G - max, H - gallery with 1 ~ m m steps). Arrows 
indicate bacterial groups. 
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The presence of extracellular matrix was also examined using Alcian Blue 
(AS) stain. No polysaccharide was seen on 1 day old biofilms, but the 5 day 
old biofilms stained positively (Fig 8.3.1.7). 
Fig 8.3.1.7: Alcian blue stain showing biofilm matrix on 5 day old S aureus 
(F2315) biofi lms (x1000). 
8.3.2 Demonstrating reduced susceptibility to antibiotics 
Demonstration of reduced susceptibility to antibiotics is a key step in showing 
that a biofilm has developed. Therefore, one day old and five day old biofilms 
were exposed to antibiotics (at different concentrations in multiples of 10 
above the minimum inhibitory concentration, MIC) for 1 day prior to sampling 
(Fig 8.3.2.1, 8.3.2.2, 8.3.2.3). Biofilms were less susceptible to antibiotics than 
planktoniC bacteria, and even antibiotic levels at 10,OOOxMIC for 1 day could 
not eradicate biofilms. 
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Fig 8.3.2.1: Biofilm bacteria (one day old) are less susceptible to antibiotics 
than planktonic (S aureus F2387). Clean control discs contained no bacteria. 
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Fig 8.3.2.2: Biofi lm bacteria (five day old) are less susceptible to antibiotics 
than planktonic (S aureus F2387). Clean control discs contained no bacteria. 
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Fig 8.3.2.3: Biofilm bacteria (five day old) are less susceptible to antibiotics 
than planktonic (S aureus F2315). Clean control discs contained no bacteria. 
8.3.3 Processing of silicone discs for analysis 
A number of methodological factors related to the model were investigated, 
using S aureus. It was important that any planktonic bacteria were removed 
prior to disc analysis. The biofilm had to be separated from the disc and 
bacteria freed to allow bacterial counting; trypsin and sonication were used to 
achieve th is, but method development required that we chose the optimum 
way of achieving th is without killing bacteria in the process. 
How many rinses are needed to remove planktonic bacteria? 
In order to assess effects of serial rinsing on bacteria we used a planktonic 
bacterial suspension in TSB placed in an Eppendorf tube for 5 minutes, and 
subjected to serial rinsing with 1 mL sterile PBS (Fig 8.3.3.1). Whilst some 
bacteria continued to be obtained after rinses 2, 3, 4 and 5 (30, 140,240, 155 
CFU/mL respectively). the largest drop in CFU was observed after the second 
rinse (approximately 1000 fold drop in CFU). This suggests that two rinses 
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remove the vast majority of bacteria, and rising an additional 3 times does not 
result in "cleaner" samples. 
For purposes of the biofilm model, three rinses were chosen when planktonic 
bacteria needed to be removed. 
Effect of serial rinsing 
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Fig 8.3.3.1: Effect of serial ri nsing on the number of bacteria obtained in each 
sequential rinse 
How long should sonication last for? 
Sonication uses ultrasound to disrupt the biofilm matrix and render bacteria 
plankton ic so that they can be grown and counted on an agar plate. Biofilm 
discs, in 1 ml of PBS in an Eppendorf tube, were placed into a water bath at 
3r c, and 50 Hz sonication applied (Precision Ultrasonic Cleaning, Ultrawave, 
Card iff, UK). The resulting bacteria l suspension in PBS was plated onto a 
sheep blood agar plate. 
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To determine appropriate sonication times to remove attached bacteria, the 
disc was sonicated for 5 minutes and the bacterial suspension plated, and the 
disc was then sonicated again to see if more bacteria could be removed from 
the disc; the different time periods thus relate to one disc. Sonication time of 5 
minutes extracted the majority of bacteria (Fig 8.3.3.2), but 10 and 15 minutes 
also continued to extract a smaller number of bacteria (1075 and 220 
CFU/mL, respectively). No bacteria were obtained after sonication for 30 or 45 
minutes, suggesting that 15 min is an adequate sonication time to recover all 
attached bacteria (when sonication is used without trypsin). 
Effect of sonication times 
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Fig 8.3.3.2: Effect of sonication time on the number of bacteria obtained from 
biofilms growing on silicone discs. No bacteria were seen after 30 and 45 
minutes. 
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Does adding trypsin before sonication increase bacterial yield? 
Trypsin is a proteolytic enzyme that disrupts biofilm attachment to render 
bacteria planktonic. A range of trypsin (trypsin 0.25% with EDT A 0.02%, 
Sigma, Gill ingham UK) incubation times prior to sonication was trialled and 
combined with different sonication times (Fig 8.3.3.3). In this experiment, 
rather than repeated sonication of a disc for increasing time periods (as in 
previous experiment Fig 8.3.3.2), each time period represents a different disc. 
Effect of trypsin and sonication 
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Fig 8.3.3.3: Effect of trypsin and sonication times on bacterial yields from 
biofi lms growing on silicone discs. 
As in the previous experiment, in the absence of trypsin, 15 min sonication is 
most effective. However, combining trypsin with sonication shows that the 
highest yield is obtained with a 15 minute incubation in trypsin and sonication 
for 5 minutes (1.1 x 105 more CFU obtained than the nearest rival, and 3.5 x 
105 more CFU than the greatest yield obtained with sonication alone in the 
absence of trypsin). Although overall the yield has changed by less than a 
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factor of 10, adding trypsin demonstrated a trend towards increased bacterial 
yield and therefore trypsinisation was incorporated into the protocol. 
Could trypsin be used without sonication? 
Bacterial counts were also performed using the finalised protocol of 15 min 
trypsin, single rinse, and 5 min sonication. Bacterial counts after sonication 
were greater than after trypsin alone (unpaired t test p=O.018) (Fig 8.3.3.4), 
confi rming that sonication increases yield compared to trypsin alone. 
Can trypsin be used without 
sonication? 
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Fig 8.3.3.4: Bacterial counts after trypsin only versus after addition of 
sonication . 
What is the effect of PBS rinse after trypsinisation? 
Two experiments were conducted to ensure that rinsing after trypsinisation (to 
remove the enzyme) does not remove a significant number of bacteria. Firstly, 
bacterial counts were performed on trypsin solution itself after 15 min 
incubation with the biofilm disc, then on the PBS after three rinses, and then 
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on the sonicated fluid . As expected the trypsin solution itself has a high 
number of CFU (Fig 8.3.3.5) , which falls once trypsin is removed and replaced 
by PBS. Sonication increases CFU, but the overall difference in number is 
small (ANOVA p=O.169). The finalised protocol also included only a single 
PBS rinse, and not 3 rinses as in this experiment. 
Trypsinisation, rinsing and 
sonication 
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Fig 8.3.3.5: Bacterial counts in trypsin , after 3 rinses, and after sonication. 
In a further experiment, rather than a rinse after trypsinisation, the trypsin 
solution itself was subject to sonication, and bacterial counts compared with 
those seen when one PBS rinse took place prior to sonication (Fig 8.3.3.6). 
This showed that performing a single PBS rinse after trypsinisation did not 
have a significant effect on the number of CFU (unpaired t test p=O.605). This 
allowed incorporation of a single PBS rinse into the method to avoid leaving 
bacteria in trypsin for extended periods of time. 
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Effect of PBS rinse after trypsin 
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Fig 8.3.3.6: Sonication in trypsin versus one PBS rinse before sonication. 
Does sonication affect bacterial viability? 
To ensure that sonication did not kill bacteria, a planktonic bacterial 
suspension was sonicated for varying time periods and plated (Fig 8.3.3.7). 
There was no evidence of sonication affecting bacterial viability, although 
experiments above indicate that longer sonication (or trypsinisation) times did 
not necessarily increase bacterial numbers obtained from the silicone disc. 
The rise in counts after sonication compared to the initial suspension probably 
represent a degree of bacterial clumping in the initial suspension and their 
dispersion with sonication. 
160 
Effect of sonication on bacteria 
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Fig 8.3.3.7: Effect of sonication on bacterial viability. 
8.3.4 Antibiotics 
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Antibiotics were added to achieve the final concentrations shown in Table 
8.3.4 .1 . The lowest concentration was chosen as it represented the MIC of the 
S aureus used in the experiments tested on Etest strip (rifampicin typically 
0.003 - 0.006 mg/L and clindamycin 0.064 - 0.125 mg/L), with remaining 
calculated concentrations increasing by a factor of 10. 
DOSE RIFAMPICIN mgIL CLiNDAMYCIN mgIL 
1MIC 0.006 0.1 
10MIC 0.06 1 
100MIC 0.6 10 
1,OOOM IC 6 100 
10,OOOM IC 60 1000 
. . Table 8.3.4.1: AntibiotiC concentrations In blofilm models 
Do antibiotics remain effective for duration of experiment? 
To ensure that antibiotics remain effective for the duration of the experiment, 
21 day old antibiotic and TSB solution used in biofilm eradication experiments 
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was mixed with Iso-Sensitest agar to make an agar plate containing rifampicin 
and dindamycin, at concentrations equivalent to the MIC for the test Staph 
aureus organism. The antibiotic mix was still effective 21 days into the 
experiment as no bacteria grew on the plate. 
Is there any antibiotic in washings or discs after detachment protocol? 
To ensure that no antibiotic is present on the discs themselves or in the 
washings after bacterial detachment protocol, the sonication solution from 
dean discs with 10,OOOMIC antibiotic dose was mixed with bacterial inoculum 
on a blood agar plate overnight. There was no difference in bacterial count 
between plates incubated just with bacteria, and those incubated with the 
addition of sonicated fluid. 
Does immediate addition of antibiotics to freshly-prepared discs inhibit 
bacteria, i.e. can antibiotics prevent biofilm formation / establishment? 
The effect of antibiotics on bacteria attached to discs for 2-3 hours was 
investigated by adding antibiotics to the models immediately after the discs 
were placed into bijoux bottles. Antibiotics at MIC levels were able to inhibit 
bacterial growth on such freshly-prepared discs. 
8.3.5 Culture results and the LiveDead stain 
A comparison of culture results and LiveDead stain results was undertaken 
(Table 8.3.5.1) on those samples that had both culture and Live Dead stain 
done as part of the assessment of antibiotic solution effectiveness on 1 and 5 
day old biofilms (data and images shown in the section on biofilm eradication 
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using antibiotic solutions). The table shows that 7% of the culture-negative 
samples were LiveDead stain positive, and 4.8% of the LiveDead stain 
negative samples were culture positive. However, the Kappa value was 0.791, 
suggesting that the agreement was substantial. Taking culture result as the 
gold standard, the sensitivity of Live Dead stain was 88.2%, specificity 93%, 
positive predictive value 83.3% and negative predictive value 95.2%. If one 
assumes that the Live Dead stain is the gold standard, the sensitivity of cu\ture 
was 83.3%, its specificity 95.2%. positive predictive value 88.2% and negative 
predictive value 93%. 
Live Dead stain 
naa DOS Total 
Culture neg Count 40 3 43 
% within culture 93.0% 7.0% 100.0% 
% within LD 95.2% 16.7% 71.7% 
% of Total 66.7% 5.0% 71.7% 
POs Count 2 15 17 
% within culture 11.8% 88.2% 100.0% 
% within LD 4.8% 83.3% 28.3% 
% ofTotal 3.3% 25.0% 28.3% 
Total Count 42 18 60 
% within culture 70.0% 30.0% 100.0% 
% within LD 100.0% 100.0% 100.0% 
% of Total 70.0% 30.0% 100.0% 
Table 8.3.5.1: Correlation between culture results and the Live Dead (LD) 
stain. 
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8.4 DISCUSSION 
8.4.1 Summary of findings 
Biofilms are defined as structured communities of bacteria attached to a 
surface and encased in self-produced extracellular matrix, and exhibiting 
reduced susceptibility to antibiotics compared to the planktonic bacteria from 
which the biofilm originates from (Parsek and Singh 2003). Any in vitro biofilm 
model, as a representation of a biofilm infection, therefore should contain both 
the physical and functional characteristics, with demonstration of reduced 
susceptibility to antibiotics essential (Donlan and Costerton 2002). 
The data presented in this chapter show that biofilms can be established on 
silicone discs, and their presence confirmed by demonstrating both their 
structure and reduced susceptibility to antibiotics that typifies biofilms 
functionally. Five day old biofilms were chosen for further study. The optimum 
processing strategy to remove attached biofilms to render bacteria planktoniC 
and thus allow their counting was also determined, with a final protocol of 
three PBS rinses, 15 minutes in trypsin, changing trypsin for PBS and then 
sonication for 5 minutes chosen. 
8.4.2 Biofilm structure and reduced susceptibility to antibiotics 
Rough silicone was chosen as the surface for biofilm attachment. Different 
surfaces vary in their biofilm susceptibility, but silicone has been found in most 
studies to be very conducive to biofilm development (Schinabeck and 
Ghannoum 2006) (Darouiche 2001) (Pascual 2002), whilst a rough surface 
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also enhances bacterial attachment (Schinabeck and Ghannoum 2006) 
(Darouiche 2001). Although biofilms formed in high shear environments may 
be stronger (Donlan and Costerton 2002), we used only a rotatory shaker for 
one hour, as the middle ear itself is unlikely to be exposed to significant shear 
forces. 
Biofilm structure 
The biofilm structure was demonstrated using a combination of SEM, confocal 
microscopy and A1cian blue polysaccharide stain. Environmental Scanning 
Electron Microscopy (ESEM) was also used, although the degree of hydration 
made the identification of individual bacteria in such images more difficult. 
Both SEM and ESEM image a sample by scanning it with a high energy 
electron beam in a raster pattern, with electrons interacting with the atoms in 
the sample to produce signals that give information about the surface of the 
sample, its composition and also electrical conductivity. However, in SEM the 
entire process is conducted in a vacuum, thus requiring the sample to be 
dehydrated. In the case of biofilms, this dehydration affects the matrix that 
contains a large amount of water, and the final images largely do not show 
much matrix. This does give rise to good photographs, as individual bacteria 
are easily seen. In the case of ESEM, technological modifications allow 
examination of hydrated structures by placing the specimen in a hydrated 
chamber rather than a vacuum; by these means the biofilm matrix can be 
preserved, but this means that individual bacteria are not seen as well 
because they are surrounded by matrix. 
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SEM gives surface characteristics of the bacteria, but LCSM is better at 
showing the three-dimensional nature of biofilms. LCSM works on the 
principle of optical sectioning, where images are collected point by point at 
selected depths and reconstructed using dedicated software (in conventional 
microscopy images from different depths are superimposed but in LCSM 
images from different depths can be portrayed separately). Thus LCSM allows 
one to determine the three-dimensional nature of biofilms by collecting images 
from different depths of a biofilm. A superimposed composite image showing 
maximum staining is also generated by the software. Using LCSM in 
conjunction with the LiveDead stain also allows the confirmation that bacteria 
in biofilms are alive. 
Alcian blue has previously been used to stain biofilms and can also be used to 
quantify extracellular matrix production (Bayston and Rodgers 1990) (Bober 
2005); it is a copper dye that reacts with polysaccharides to form an insoluble 
precipitate (Ramus 1977). The advantage of Alcian blue staining is that, 
because polysaccharide is an essential component of biofilm matrix (Lasa 
2006), the stain should at least in theory detect the matrix of all biofilms. 
Various other stains for biofilm matrix can also be used, including a number of 
commercially available stains that can detect a variety of different matrix 
components (Invitrogen 2011). 
Reduced susceptibility to antibiotics 
In terms of reduced susceptibility to antibiotics, a difference could be seen 
between planktonic and biofilm bacteria after 24 hours of antibiotic treatment, 
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with biofilm bacteria not inhibited by any antibiotic concentration tested, but 
planktonic ones inhibited by antibiotics at a concentration of 100 times higher 
than the MIC of the inoculum. The reason for planktonic bacteria requiring 
100MIC (rather than actual MIC level) probably lies in the fact that antibiotic 
treatment was carried out only for 24 hours. Rifampicin can be bacteriostatic 
or bactericidal depending on dose and exposure time, and exhibit time -
dependent and also concentration - dependent killing (Gumbo, et al. 2007) 
(Bakker-Woudenberg, et al. 2005). Similarly, clindamycin can be bacteriostatic 
or bactericidal depending on dose and exposure time, and exhibit time -
dependent (Klepser, et al. 1996) and also concentration - dependent killing 
(Aldridge and Stratton 1991). This is thought to explain the fact that a higher 
antibiotic concentration than MIC is required to inhibit planktonic bacteria at 24 
hours. At longer incubation periods, even in the planktonic samples biofilm 
"slime" could be seen to develop at the bottom of a bijoux tube in the 
planktonic samples; thus data seen at longer time intervals are unlikely to 
represent pure planktonic bacteria. 
Effect of biofilm age 
Although communities of attached bacteria could be seen with SEM both in 1 
and 5 day old biofilms, polysaccharide could be shown only on 5 day old 
biofilms. The observation that attached bacteria on both 1 and 5 day old discs 
exhibited greatly reduced susceptibility to antibiotics compared to planktonic 
bacteria suggests that attached bacteria develop recalcitrance to antibiotics 
before they start producing a significant amount of polysaccharide matrix, in 
keeping with previous literature (Otto 2008) (Dagostino, Goodman and 
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Marshall 1994). Later experiments on biofilm eradication (data shown in next 
chapter) showed that no great difference was seen when 5 day old biofilms 
were compared with 14 and 21 day old ones, suggesting that the S 8ureus 
biofilm seen at 5 days was a mature one and therefore suitable for further 
studies involving a modified release antibiotic implant. 
Our findings of the early development of reduced antibiotic susceptibility are 
comparable to other studies that have found biofilms forming as soon as at 24 
hours (Vorachit, et al. 1993) (Nickel, et al. 1985) (Oliveira, et al. 2007), and 
that biofilm age is not necessarily a major factor influencing susceptibility to 
antibiotics (Wong, et al. 2010). This poses a potential problem when trying to 
eradicate biofilms, for if bacteria develop reduced susceptibility very early 
upon contacting a surface, then the higher antibiotic doses will be needed 
right from an early biofilm age. In the context of infections on prosthetic 
implants, this then becomes a major issue emphasising the importance of 
prevention of infection in the first place (for example with the use of antibiotic-
impregnated biomaterials (Bayston, Fisher and Weber 2009) (Bayston, Vera 
and Ashraf 2010), although our findings that almost immediate addition of 
antibiotics to "infected" silicone discs (within a few hours and presumably 
before biofilms form) can prevent bacterial growth is consistent with the 
concept of peri-operative antibiotics as a way of minimising prosthesis 
infection. 
In the context of OME though, the fact that biofilm age may be relatively 
unimportant could be an advantage. By the time children are treated biofilms 
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will probably have been present for months (at least 3 months if the NICE 
guidelines recommended 3 month waiting period is followed, and probably 
much longer as disease is likely to have been present months before clinical 
advice is sought). If biofilm age was a major stumbling block in biofilm 
eradication, then trying to eradicate biofilms that are months old would be 
difficult. However, if biofilms can be eradicated with biofilm age having a small 
role only, then the strategy of trying to eradicate OME biofilms could be a 
successful one. Certainly our results show that there is no significant 
difference in recalcitrance between biofilms aged between 5 and 21 days (also 
see Chapter 9), suggesting that eradication of biofilms several weeks old may 
be possible (providing appropriately high antibiotic levels are used for a long 
time period). We have not studied biofilms that are "months" old, but if 
reduced susceptibility develops on the first day, and there is not much 
difference in antibiotic susceptibility of biofilms within the first few weeks 
(Wong, et al. 2010), it may be tempting to speculate that eradication of 
"months" old biofilms may also be possible. However, the influence of biofilm 
age on its susceptibility to eradication remains an important issue. 
8.4.3 Processing of biofilm discs 
Biofilm bacteria attached to surfaces may be difficult to culture using standard 
laboratory techniques, but if the biofilm matrix is disrupted and bacteria 
rendered planktonic, then they should grow under standard laboratory 
conditions. This study therefore investigated different sonication times and 
trypsinisation times as a means of detaching bacteria from the silicone disc. 
On the whole, the differences between groups are smaller than a factor of 10. 
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Prolonged sonication and trypsin exposure (30 minutes) did appear to reduce 
bacterial yield, although tests on planktonic bacteria did not show any 
evidence of bacterial killing by sonication; previous work also suggests that 
ultrasound has little effect on Gram positive bacteria, but it inhibits many Gram 
negative ones (Monsen, et al. 2009). As trypsin is a proteolytic enzyme, 
prolonged exposure may affect bacterial viability, therefore a decision was 
made to remove trypsin after 15 min and replace with PBS before sonication 
(alternatives would have been to use a trypsin inhibitor, or to change pH or 
temperature to reduce trypsin activity). On the basis that the combination of 15 
min trypsin and 5 min sonication yielded the highest count, that combination 
was chosen for future experiments. A number of methodological factors in the 
model were also investigated, so that we were able to establish that rinsing 
the discs three times removes majority of non-attached bacteria, that 
antibiotics remain effective for the duration of the experiments, and that no 
antibiotic remains on the discs after rinsing. 
Although other studies have used broth turbidity (Ceri, et al. 1999) or in situ 
staining of bacterial biofilms with stains such as crystal violet (Djordjevic, 
Wiedmann and McLandsborough 2002) as a means of identifying bacteria, we 
chose to count colony forming units (CFU) as we felt that this represented a 
more accurate analysis of biofilm growth, particularly when one is looking at 
small numbers of CFU in resuscitation experiments. Therefore, bacteria had to 
be detached from the surface and rendered planktonic to allow CFU counting. 
Trypsin, used to aid detachment, is a proteolytic enzyme that has previously 
been utilised to remove biofilms from surfaces (Rocha, et al. 2008) (Chaignon, 
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et al. 2007). and is widely used in tissue culture to detach cells from a surface. 
It has also been used in an attempt to produce a biofilm-resistant surface by 
attaching trypsin enzyme to a stainless steel surface (Caro. et al. 2010). 
Sonication has also been widely used in biofilm detachment (Monsen, et al. 
2009). and may also have future clinical applications as a possible diagnostic 
tool (Bonkat. et al. 2010) or an in vivo biofilm removal aid. We used an 
ultrasonic bath, where the generated ultrasound waves travel through water to 
create compression waves and local cavitation in contact with surfaces, 
leading to disruption of the biofilm's attachment to the silicone disc. Although 
we chose trypsinisation and sonication in our method, the processing of 
biofilms for analysis does vary in different methods I models, for example the 
well known Calgary biofilm device typically recommends only sonication to 
remove attached bacteria (Innovotech MBEC 2011 ). 
We used rinsing to remove the antibiotic, as residual antibiotic could interfere 
with bacterial growth on agar plates following processing. This would be a 
particular problem if planktonic bacteria were plated with a solution containing 
antibiotics: although the antibiotic level may be too low to inhibit biofilms, it 
may be high enough to affect the planktonic bacteria newly-released from the 
biofilm. Our experiments indicated that the solution did not inhibit bacterial 
growth. An altemative to the rinsing would have been to incorporate an 
antibiotic neutral ising step. as solutions that inhibit specific antibiotics are 
available, as is a universal neutralising solution (Innovotech MBEC 2011). 
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Although the two antibiotics would be unlikely to lose significant activity in 3 
weeks, the continued effectiveness of antibiotics for the duration of the 
experiment was also examined, with no evidence that antibiotic effectiveness 
was lost. However, the method did not formally assay the concentration of 
antibiotics separately. This could have been done using HPLC or a biological 
method such as formal broth dilution (assaying the two antibiotics 
independently), but for the purposes of these experiments knowing that there 
is no significant deterioration of activity was felt to be sufficiently accurate. 
Clindamycin is very stable, but rifampiCin can deteriorate if exposed to excess 
sunlight (Bhutani, Mariappan and Singh 2004), so the biofilm models and 
antibiotic solutions were kept away from direct sunlight. 
8.4.4 Other biofilm models 
Other established biofilm models are also available, the best known being the 
Calgary MBEC device (Ceri, et al. 1999) that allows high throughput analysis 
of biofilm grown on pegs suspended in a micro-titre plate (Fig 8.4.4.1), but the 
dimensions of the micro-titre plate wells are too small to be used as a middle 
ear model. Another commercially available device is the CDC biofilm reactor 
that is composed of discs (made of a variety of possible materials) suspended 
in a 1 litre flow chamber (Fig 8.4.4.2) (Goeres, et al. 2005), but the dimensions 
of this would again not be suitable as a middle ear approximation. Other in 
vitro models include the modified Robbins device where biomaterial samples 
are suspended in a flow chamber, and various models of biofilms grown on 
discs of glass or metal. As our aim was to develop a model in which we could 
test the antibiotic pellet, we needed to have something with the dimensions 
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that would allow the pellet to be placed into the nutrient broth together with the 
biofilm. Th is meant that the commercial Calgary device and CDC biofilm 
reactor were not suitable , and we had to develop a new model. 
A Peg 
Fig 8.4.4.1 The Calgary device - MBEC ™ high throughput assay (picture from 
manufacturer's website) (Ceri, et al. 1999) (Innovotech MBEC 2011) 
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Fig 8.4.4.2 The CDC Biofilm Reactor 
(picture from manufacturer's website) 
(BiosurfaceTechnologies 2011). Discs 
of various materials are held within 
holders, suspended in a large 
chamber of fluid . 
In addition to allowing the testing on antibiotic pellets with dimensions based 
on those of the middle ear, the model developed above is also useful because 
determination of bacterial counts is possible with the ability to detect only a 
small number of surviving bacteria. This is important when studying biofilm 
eradication, although in life one may expect the body's immune system to deal 
easily with only a handful of bacteria so that the presence of a few surviving 
bacteria in vitro may be of limited clinical importance (although it may lead to 
res istance ). 
Although useful for the study of biofilm eradication with antibiotic pellets sized 
for the middle ear, the model described above is very labour-intensive. Each 
silicone disc is processed individually by hand, and with experiments typically 
consisting of more than a 100 discs at a time the amount of time required to 
process the discs is substantial. Thus the model does not lend itself to mass 
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study of biofilms, where the Calgary device has distinct advantages. A 
possible modification of our system would be to use multi-well plates with 
larger wells, for example the 24 well plates would accommodate just under 2 
mL of fluid, although the addition of the disc and pellet would reduce the 
volume of nutrient broth. If multi-well plates were used, there would also be 
concern about contamination from well to well during rinsing and sonication, or 
even during incubation as the wells are not individually sealed like the bijoux 
bottles in our model (the amount of handling required in our model is also a 
risk for contamination, although after initial trials contamination did not appear 
to be a major issue). The Calgary device gets around this issue by having 
pegs in each well, but as at present it is available only with the small wells of a 
96 well plate (typically less than a third of a millilitre) it could not accommodate 
antibiotic pellets. As an alternative to the silicone discs, one could have 
developed a Calgary "well and peg" type device but sized it for a larger well. It 
may also have been possible to "scale" up or down and use a bigger pellet in 
a bigger model or a smaller pellet in the Calgary device, but due to concerns 
about the effect that scaling might have this was not felt appropriate. 
In terms of the in vitro model and processing of the silicone discs, an 
important consideration is applicability to other situations. Apart from the 
limitations of this model compared to others detailed above, the establishment 
of biofilms, timing, and processing that were developed in our laboratory for S 
aureus on a specific scale can be considered relevant only to this situation. 
Investigations in other laboratories, with different scales and different bacteria 
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would necessitate validation and optimisation of the in vitro model in the same 
way. 
An interesting aspect of in vitro biofilm study is the use of conditioning films 
composed of a variety of components (fibronectin, fibrinogen, fibrin, albumin, 
collagen, elastin, von Willebrand factor) (Schinabeck and Ghannoum 2006) 
(Pascual 2002). Some biofilm models use this as a means of coating an 
artificial surface to make it more conducive to biofilm attachment (Frade and 
Arthington-Skaggs 2010), but the presence of a conditioning film is not 
thought to be crucial for biofilm formation by other studies (Bayston, Ashraf, et 
al. 2007); it may be that its importance (or not) depends on the bacterial 
species, the surface, stress forces and nutritional provision. It is also 
interesting that the conditioning film may have clinical relevance, with a study 
of ureteric stents finding that the presence of certain proteins is highly 
associated with subsequent stent encrustation and biofilm colonisation 
(Canales, et al. 2009), and a study of dental caries finding that saliva as a 
conditioning film promotes biofilm formation (Shimotoyodome, et al. 2007). In 
the model described in this thesis the biofilms formed without the need for a 
conditioning film, therefore its use was not examined. 
8.4.5 Culture results and the LiveDead stain 
When assessing the presence of live bacteria, the samples can be analysed 
by microbial culture, but the LiveDead stain may also have a role, for example 
if biofilm bacteria will not grow on an agar plate they can at least be identified 
as live by the Live Dead stain. As culture and LiveDead stain theoretically test 
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the same thing, i.e. the presence of live bacteria, they could be expected to 
give very similar if not identical results. In fact 7% of the culture-negative 
samples were Live Dead positive, and 4.8% of the LiveDead-negative samples 
were culture-positive. The Kappa value was 0.791, suggesting the agreement 
was substantial (Kappa range of 0.61-0.80 is considered as substantial 
agreement, and values of 0.81 or more as almost perfect agreement) (Landis 
and Koch 1977). Further, there was no evidence that culture systematically 
under-estimated the number of bacteria detected by the Live Dead stain. The 
Live Dead stain does have a small rate of falsely labelling bacteria as live, as 
described in the discussion of OME aetiology section. 
Early experiments analysed biofilms both with culture and the Live Dead stain, 
but as the data above indicates both can be considered to measure the same 
thing. The advantage of culture was of course that it gave a quantitative result 
(although the Live Dead stain could also have been adapted to be quantitative 
e.g. by counting the number of bacteria per microscope field). Due to 
concerns about a small risk of falsely labelling bacteria as live using Live Dead 
stain it was felt better to rely only on culture results rather than using Live Dead 
or indeed both culture and LiveDead staining when determining biofilm 
eradication. 
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8.5 BIOFILM MODEL: CONCLUSION 
Although many biofilm models have been described, and commercially 
available kits exist, the specific plans to test biofilm eradication using an 
antibiotic pellet sized for the middle ear required the development of a new 
biofilm model. The model consists of biofilms grown on a silicone discs, with 
biofilm presence confirmed by showing the structure of biofilms as well as 
their reduced susceptibility to antibiotics. The best way of assessing biofilm 
eradication is to look for and count any remaining bacteria, therefore a 
strategy to detach biofilm bacteria and render them planktonic prior to 
counting had to be developed. A number of methodological parameters were 
therefore investigated, with the final method of biofilm detachment chosen to 
consist of trypsinisation for 15 minutes, change of trypsin to PBS and then 
sonication for 5 minutes, with plating of the resultant suspension. 
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